

PCL Department Publications (2015)

Al-Awar R

Sun Y, Bell JL, Carter D, Gherardi S, Poulos RC, Milazzo G, Wong JW, **Al-Awar R**, Tee AE, Liu PY, Liu B, Atmadibrata B, Wong M, Trahair T, Zhao Q, Shohet JM, Haupt Y, Schulte JH, Brown PJ, Arrowsmith CH, Vedadi M, MacKenzie KL, Hüttelmaier S, Perini G, Marshall GM, Braithwaite A, Liu T. WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma. *Cancer Res.*; 75(23):5143-54, 2015.

Grebien F, Vedadi M, Getlik M, Giambruno R, Grover A, Avellino R, Skucha A, Vittori S, Kuznetsova E, Smil D, Barysytte-Lovejoy D, Li F, Poda G, Schapira M, Wu H, Dong A, Senisterra G, Stukalov A, Huber KV, Schönegger A, Marcellus R, Bilban M, Bock C, Brown PJ, Zuber J, Bennett KL, **Al-Awar R**, Delwel R, Nerlov C, Arrowsmith CH, Superti-Furga G. Erratum: Pharmacological targeting of the Wdr5-MLL interaction in C/EBP α N-terminal leukemia. *Nat Chem Biol.*; 11(10):815, 2015.

Zhu J, Sammons MA, Donahue G, Dou Z, Vedadi M, Getlik M, Barysytte-Lovejoy D, **Al-Awar R**, Katona BW, Shilatifard A, Huang J, Hua X, Arrowsmith CH, Berger SL. Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. *Nature*. Sep 10;525(7568):206-11, 2015.

Grebien F, Vedadi M, Getlik M, Giambruno R, Grover A, Avellino R, Skucha A, Vittori S, Kuznetsova E, Smil D, Barysytte-Lovejoy D, Li F, Poda G, Schapira M, Wu H, Dong A, Senisterra G, Stukalov A, Huber KV, Schönegger A, Marcellus R, Bilban M, Bock C, Brown PJ, Zuber J, Bennett KL, **Al-Awar R**, Delwel R, Nerlov C, Arrowsmith CH, Superti-Furga G. Pharmacological targeting of the Wdr5-MLL interaction in C/EBP α N-terminal leukemia. *Nat Chem Biol.*; 11(8):571-8, 2015.

Wang Z, Dove P, Wang X, Shamas-Din A, Li Z, Nachman A, Oh YJ, Hurren R, Ruschak A, Climie S, Press B, Griffin C, Undzys E, Aman A, **Al-Awar R**, Kay LE, O'Neill D, Trudel S, Slassi M, Schimmer AD. FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing. *Cell Death Dis.*; 6:e1815, 2015.

Cole A, Wang Z, Coyaud E, Voisin V, Gronda M, Jitkova Y, Mattson R, Hurren R, Babovic S, Maclean N, Restall I, Wang X, Jeyaraju DV, Sukhai MA, Prabha S, Bashir S, Ramakrishnan A, Leung E, Qia YH, Zhang N, Combes KR, Ketela T, Lin F, Houry WA, Aman A, **Al-Awar R**, Zheng W, Wienholds E, Xu CJ, Dick J, Wang JC, Moffat J, Minden MD, Eaves CJ, Bader GD, Hao Z, Kornblau SM, Raught B, Schimmer AD. Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia. *Cancer Cell*; 27(6):864-76, 2015.

Bernard D, Gebbia M, Prabha S, Gronda M, MacLean N, Wang X, Hurren R, Sukhai MA, Cho EE, Manolson MF, Datti A, Wrana J, Minden MD, **Al-Awar R**, Aman A, Nislow C, Giaever G, Schimmer AD. Select microtubule inhibitors increase lysosome acidity and promote lysosomal disruption in acute myeloid leukemia (AML) cells. *Apoptosis*; 20(7):948-59, 2015.

Andreazza AC

Gonçalves VF, **Andreazza AC**, Kennedy JL. Mitochondrial dysfunction in schizophrenia: an evolutionary perspective. *Hum Genet.*; 134(1):13-21, 2015.

Nascimento C, Kim HK, Young LT, Mendonça KM, Grinberg LT, Lafer B, **Andreazza AC** Glutathione-mediated effects of lithium in decreasing protein oxidation induced by mitochondrial complex I dysfunction. *J Neural Transm (Vienna).*; 122(6):741-6, 2015.

Scola G, **Andreazza AC** The role of neurotrophins in bipolar disorder. *Prog Neuropsychopharmacol Biol Psychiatry*; 56:122-8, 2015.

Andreazza AC, Gildengers A, Rajji TK, Zuzarte PM, Mulsant BH, Young LT. Oxidative stress in older patients with bipolar disorder. *Am J Geriatr Psychiatry*; 23(3):314-9, 2015.

Bond DJ, **Andreazza AC**, Hughes J, Dhanoa T, Torres IJ, Kozicky JM, Young LT, Lam RW, Yatham LN. Association of peripheral inflammation with body mass index and depressive relapse in bipolar disorder. *Psychoneuroendocrinology.*; 65:76-83, 2015.

Andreazza AC, Barakauskas VE, Fazeli S, Feresten A, Shao L, Wei V, Wu CH, Barr AM, Beasley CL. Effects of haloperidol and clozapine administration on oxidative stress in rat brain, liver and serum. *Neurosci Lett.*; 591:36-40, 2015.

A meta-analysis of lipid peroxidation markers in major depression. Mazereeuw G, Herrmann N, **Andreazza AC**, Khan MM, Lanctôt KL. *Neuropsychiatr Dis Treat.*; 11:2479-91, 2015.

Targeting mitochondrial RNA polymerase in acute myeloid leukemia. Bralha FN, Liyanage SU, Hurren R, Wang X, Son MH, Fung TA, Chingcuanco FB, Tung AY, **Andreazza AC**, Psarianos P, Schimmer AD, Salmena L, Laposa RR. *Oncotarget.*; 6(35):37216-28, 2015.

The link between mitochondrial complex I and brain-derived neurotrophic factor in SH-SY5Y cells--The potential of JNX1001 as a therapeutic agent. Kim HK, Mendonça KM, Howson PA, Brotchie JM, **Andreazza AC**. *Eur J Pharmacol.*; 764:379-84, 2015.

Translational Research in Bipolar Disorders. Machado-Vieira R, Frey BN, **Andreazza AC**, Quevedo J. *Neural Plast.*; 2015:576978. Similar articles Select item 26075098.

The Potential Role of the NLRP3 Inflammasome as a Link between Mitochondrial Complex I Dysfunction and Inflammation in Bipolar Disorder. Kim HK, Chen W, **Andreazza AC**. *Neural Plast.*; 2015:408136. Similar articles Select item 25754104.

Andreazza AC, Young LT. Acta Psychiatr Scand.; 131(5):397-8, 2015. Select item 25684243

Arnot JA

Arnot JA, Quinn CL. Development and evaluation of a database of dietary bioaccumulation test data for organic chemicals in fish. Environ Sci Technol.; 49(8):4783-96, 2015.

Shin HM, Ernstoff A, **Arnot JA**, Wetmore BA, Csiszar SA, Fantke P, Zhang X, McKone TE, Jolliet O, Bennett DH. Risk-Based High-Throughput Chemical Screening and Prioritization using Exposure Models and in Vitro Bioactivity Assays. Environ Sci Technol.; 49(11):6760-71, 2015.

Xiao R, **Arnot JA**, MacLeod M. Towards an improved understanding of processes controlling absorption efficiency and biomagnification of organic chemicals by fish. Chemosphere.; 138:89-95, 2015.

Thomas P, Dawick J, Lampi M, Lemaire P, Presow S, van Egmond R, **Arnot JA**, Mackay D, Mayer P, Galay Burgos M. Application of the Activity Framework for Assessing Aquatic Ecotoxicology Data for Organic Chemicals. Environ Sci Technol.; 49(20):12289-96, 2015.

McLeod AM, **Arnot JA**, Borgå K, Selck H, Kashian D, Krause A, Paterson G, Haffner GD, Drouillard KG. Quantifying uncertainty in the trophic magnification factor related to spatial movements of organisms in a food web. Integr Environ Assess Manage 11(2): 306-318, 2015.

Beaulieu JM

Etiévant A, Manta S, Latapy C, Magno LA, Fecteau S, Beaulieu JM. Repetitive transcranial magnetic stimulation induces long-lasting changes in protein expression and histone acetylation. Sci Rep.; 5:16873, 2015.

Lemay F, Doré FY, Beaulieu JM. Increased ethanol consumption despite taste aversion in mice with a human tryptophan hydroxylase 2 loss of function mutation. Neurosci Lett.; 609:194-7, 2015.

Del' Guidice T, Beaulieu JM. Selective disruption of dopamine D2-receptors/beta-arrestin2 signaling by mood stabilizers. J Recept Signal Transduct Res.; 35(3):224-32, 2015.

Beaulieu JM. In vivo veritas, the next frontier for functionally selective GPCR ligands. Methods.; 92:64-71, 2015.

Thériault O, Poulin H, Beaulieu JM, Chahine M. Differential modulation of Nav1.7 and Nav1.8 channels by antidepressant drugs. Eur J Pharmacol.; 764:395-403, 2015.

Beaulieu JM, Espinoza S, Gainetdinov RR. Dopamine receptors - IUPHAR Review 13. *Br J Pharmacol.*; 172(1):1-23. Review. PubMed PMID: 25671228; PubMed Central PMCID: PMC4280963, 2015.

Lavoie J, Hébert M, Beaulieu JM. Looking beyond the role of glycogen synthase kinase-3 genetic expression on electroretinogram response: what about lithium? *Biol Psychiatry.*; 77(3):e15-7, 2015.

Boutros PC

Alioto T, Buchhalter I, Derdak S, Hutter B, Eldridge MD, Hovig E, Heisler LE, Beck TA, Simpson JT, Tonon L, Sertier AS, Patch AM, Jäger N, Ginsbach P, Drews R, Paramasivam N, Kabbe R, Chotewutmontri S, Diessl N, Previti C, Schmidt S, Brors B, Feuerbach L, Heinold M, Groebner S, Korshunov A, Tarpey PS, Butler AP, Hinton J, Jones D, Menzies A, Raine K, Shepherd R, Stebbings L, Teague JW, Ribeca P, Giner FC, Beltran S, Raineri E, Dabad M, Heath SC, Gut M, Denroche RE, Harding NJ, Yamaguchi TN, Fujimoto A, Nakagawa H, Quesada V, Valdés-Mas R, Nakken S, Vodák D, Bower L, Lynch AG, Anderson CL, Waddell N, Pearson JV, Grimmond SM, Peto M, Spellman PT, He M, Kandath C, Lee S, Zhang J, Letourneau L, Ma S, Seth S, Torrents D, Xi L, Wheeler DA, Lopez-Otin C, Campo E, Campbell PJ, **Boutros PC**, Puente XS, Gerhard DS, Pfister SM, McPherson JD, Hudson TJ, Schlesner M, Lichter P, Eils R, Jones DT, Gut IG. A comprehensive assessment of somatic mutation detection in cancer using whole genome sequencing. *Nature Communications* 6:10001 (PMID: 26647970), 2015.

The Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer *Cell* 163(4):1011-1025, 2015.

Spears M, Yousif F, Lyttle N, **Boutros PC**, Munro AF, Twelves C, Pritchard KI, Levine MN, Shepherd L, Bartlett JM. A four gene signature predicts benefit from anthracyclines: Evidence from the BR9601 and MA5 clinical trials *Oncotarget* 6(31):31693-31701, 2015.

Lee J, Prokopec SD, Watson JD, Sun RX, Pohjanvirta R, **Boutros PC**. Male and female mice show significant differences in hepatic transcriptome response to 2,3,7,8- tetrachlorodibenzo-p-dioxin *BMC Genomics* 16(1):625, 2015.

Houlahan KE , Prokopec SD , Sun RX , Moffat ID, Linden J, Lensu S, Okey AB, Pohjanvirta R, **Boutros PC**. Transcriptional profiling of raw white adipose tissue response to 2,3,7,8-tetrachlorodibenzo-p-dioxin *Toxicology and Applied Pharmacology* (PMID: 26232522), 2015.

Huang X, Taeb S, Jahangiri S, Korpela E, Cadonic I, Yu N, Krylov SN, Fokas E, **Boutros PC**, Liu SK. miR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD) *Oncotarget* 6(26):22439-22451, 2015.

Boutros PC , Fraser M, Harding NJ, de Borja R⁺, Trudel D, Lalonde E, Meng A, Hennings-Yeomans PH, McPherson A, Sabelnykova VY, Zia A, Fox NS, Livingstone J, Shiah YJ, Wang J, Beck TA, Have CL, Chong T, Sam M, Johns J, Timms L, Buchner N, Wong A, Watson JD, Simmons TT, P'ng C, Zafarana G, Nguyen F, Luo X, Chu KC, Prokopec SD, Sykes J, Dal Pra

A, Berlin A, Brown A, Chan-Seng-Yue MA, Yousif F, Denroche RE, Chong LC, Chen GM, Jung E, Fung C, Starmans MH, Chen H, Govind SK, Hawley J, D'Costa A, Pintilie M, Waggott D, Hach F, Lambin P, Muthuswamy LB, Cooper C, Eeles R, Neal D, Tetu B, Sahinalp C, Stein LD, Fleshner N, Shah SP, Collins CC, Hudson TJ, McPherson JD, van der Kwast T, Bristow RG. Spatial genomic heterogeneity within localized, multi-focal prostate cancer *Nature Genetics* 47(7):736-745, 2015.

Ewing AD, Houlahan KE, Hu Y, Ellrott K, Caloian C, Yamaguchi TN, Bare JC, P'ng C, Waggott D, Sabelnykova VY, ICGC-TCGA DREAM Somatic Mutation Calling Challenge Participants, Kellen MR, Norman TC, Haussler D, Friend SH, Stolovitzky G, Margolin A, Stuart JM, **Boutros PC**. Combining accurate tumour genome simulation with crowd-sourcing to benchmark somatic single nucleotide variant detection *Nature Methods* 12(7):623-630, 2015.

Anghel CV, Quon G, Haider S, Nguyen F, Deshwar AG, Morris QD, **Boutros PC**. ISOpureR: an R implementation of a computational purification algorithm of mixed tumour profiles *BMC Bioinformatics* 16:156, 2015.

How C, Pintilie M, Bruce JP, Hui AB, Clarke BA, Wong P, Yin S, Yan R, Waggott D, **Boutros PC**, Fyles A, Hedley DW, Hill RP, Milosevic M, Liu FF. Developing a prognostic micro-RNA signature for human cervical carcinoma *PLoS One* 10(4):e0123946, 2015.

Dodbiba L, Teichman J, Fleet A, Thai H, Starmans MH, Navab R, Chena Z, Girgis H, Eng L, Espin-Garcia O, Shen X, Bandarchi B, Schwock J, Tsao MS, El-Zimaity H, Der SD, Xu W, Bristow RG, Darling GE, **Boutros PC**, Ailles LE, Liu G. Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastroesophageal junction cancers *PLoS One* 10(3):e0121872, 2015.

Bruce JP, Hui AB, Shi W, Perez-Ordóñez B, Weinreb I, Xu W, Haibe-Kains B, Waggott DM, **Boutros PC**, O'Sullivan B, Waldron J, Huang SH, Chen EX, Gilbert R, Liu FF. Identification of a microRNA Signature Associated with Risk of Distant Metastasis in Nasopharyngeal Carcinoma *Oncotarget* 6(6):4537-4550, 2015.

Cooper CS, Eeles R, Wedge DC, Van Loo P, Gundem G, Alexandrov LV, Kremeyer B, Butler A, Lynch AG, Edwards S, Camacho N, Massie CE, Kote-Jarai Z, Dennis N, Merson S, Leongamornlert D, Zamora J, Kay J, Luxton HJ, Corbishley C, Thomas S, Nik-Zainal S, Ramakrishna M, O'Meara S, Matthews L, Clark J, Hurst R, Mithen R, Bristow RG, **Boutros PC**, Fraser M, Cooke S, Raine K, Jones D, Menzies A, Stebbings L, Hinton J, Teague J, McLaren S, Mudie L, Hardy C, Anderson E, Joseph O, Goody V, Robinson B, Maddison M, Gamble S, Greenman C, Berney D, Hazell S, Livni N, The ICGC Prostate Group, Fisher C, Ogden C, Kumar P, Thompson A, Woodhouse C, Nicol D, Mayer E, Dudderidge T, Shah NC,

Gnanapragasam V, Voet T, Campbell P, Futreal A, Easton D, Warren AY, Foster CS, Stratton M, Whitaker HC, McDermott U, Brewer DS, Neal DE. Analysis of the Genetic Phylogeny of Multifocal Prostate Cancer Identifies Multiple Independent Clonal Expansions in Neoplastic and Morphologically Normal Prostate Tissue *Nature Genetics* 47(4):367-372, 2015.

Prokopec SD, Watson JD, Lee J, Pohjanvirta R, **Boutros PC**. Sex-related differences in murine hepatic transcriptional and proteomic responses to TCDD *Toxicology and Applied Pharmacology* 284(2):188-196, 2015.

Shiah Y-J, Tharmapalan P, Casey AE, Joshi PA, McKee TD, Jackson HW, Beristain AG, Chan-Seng-Yue MA, Bader GD, Lydon JP, Waterhouse PD, **Boutros PC**, Khokha R. A Progesterone-CXCR4 Axis Controls Mammary Progenitor Cell Fate in the Adult Gland CXCR4 Function in Mammary Progenitors *Stem Cell Reports* 4(3):313-322, 2015.

The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas *Nature* 517(7536):576-582, 2015.

Starmans MH, Pintilie M, Chan-Seng-Yue M, Moon NC, Haider S, Nguyen F, Lau SK, Liu N, Kasprzyk A, Wouters BG, Der SD, Shepherd FA, Jurisica I, Penn LZ, Tsao MS, Lambin P, **Boutros PC**. Integrating RAS status into prognostic signatures for adenocarcinomas of the lung *Clinical Cancer Research* 21(6):1477-1486, 2015.

Boutros PC. The path to routine use of genomic biomarkers in the cancer clinic *Genome Research* 25(10):1508-1513, 2015.

Reich HN, Sabelnykova VY, **Boutros PC**. Matching kidneys and urines: establishing non-invasive surrogates of intra-renal events in primary glomerulonephritis *Seminars in Nephrology* 35(3):256-265, 2015.

Mutation Consequences and Pathway Analysis Working Group of the International Cancer Genome Consortium Pathway and Network Analysis of Cancer Genomes *Nature Methods* 12(7):615-621, 2015.

van Gisbergen MW, Voets AM, Starmans MH, de Coo IF, Yadak R, Hoffmann RF, **Boutros PC**, Smeets HJ, Dubois L, Lambin P. How do changes in the mtDNA and mitochondrial dysfunction influence cancer and cancer therapy? Challenges, opportunities and models *Mutation Research – Reviews* 764:16-30, 2015.

Starmans MH, **Boutros PC**. Biomarkers and subtypes of cancer *Aging* 7(5):280-281, 2015.

Burnham WM

Trépanier MO, Kwong KM, Domenichiello AF, Chen CT, Bazinet RP, **Burnham WM**. Intravenous infusion of docosahexaenoic acid increases serum concentrations in a dose-dependent manner and increases seizure latency in the maximal PTZ model. *Epilepsy Behav.*; 50:71-6, 2015.

Dorian P

McKelvie RS, Heckman GA, Blais C, Cox JL, Ezekowitz JA, Gong Y, Harkness K, Moe G, Dai S, **Dorian P**, Johnstone DE, McGeachie EC, Tu JV, Lambert LJ. Canadian Cardiovascular Society Quality Indicators for Heart Failure. *Can J Cardiol.*; 32(8):1038.e5-9, 2015.

Tran C, Bennell MC, Qiu F, Ko DT, Singh SM, **Dorian P**, Atzema CL, Bhatia RS, Wijeyesundera HC. Predictors and clinical outcomes of inpatient versus ambulatory management after an emergency department visit for atrial fibrillation: A population-based study. *Am Heart J.*; 173:161-9, 2015.

Nichol G, Leroux B, Wang H, Callaway CW, Sopko G, Weisfeldt M, Stiell I, Morrison LJ, Aufderheide TP, Cheskes S, Christenson J, Kudenchuk P, Vaillancourt C, Rea TD, Idris AH, Colella R, Isaacs M, Straight R, Stephens S, Richardson J, Condle J, Schmicker RH, Egan D, May S, Ornato JP; ROC Investigators.. Trial of Continuous or Interrupted Chest Compressions during CPR. *N Engl J Med.*; 373(23):2203-14, 2015.

Czarnecki A, Morrison LJ, Qiu F, Cheskes S, Koh M, Wijeyesundera HC, Verbeek PR, Austin PC, **Dorian P**, Scales DC, Tu JV, Ko DT. Association of prior β -blocker use and the outcomes of patients with out-of-hospital cardiac arrest. *Am Heart J.*; 170(5):1018-1024.e2, 2015.

Lip GY, Lanitis T, Kongnakorn T, Phatak H, Chalkiadaki C, Liu X, Kuznik A, Lawrence J, **Dorian P**. Cost-effectiveness of Apixaban Compared With Edoxaban for Stroke Prevention in Nonvalvular Atrial Fibrillation. *Clin Ther.*; 37(11):2476-2488.e27, 2015.

Angaran P, **Dorian P**, Tan MK, Kerr CR, Green MS, Gladstone DJ, Mitchell LB, Fournier C, Cox JL, Talajic M, Lin PJ, Langer A, Goldin L, Goodman SG. The Risk Stratification and Stroke Prevention Therapy Care Gap in Canadian Atrial Fibrillation Patients. *Can J Cardiol.*; 32(3):336-43, 2015.

Macle L, Cairns JA, Andrade JG, Mitchell LB, Nattel S, Verma A; CCS Atrial Fibrillation Guidelines Committee.. The 2014 Atrial Fibrillation Guidelines Companion: A Practical Approach to the Use of the Canadian Cardiovascular Society Guidelines. *Can J Cardiol.*; 31(10):1207-18, 2015.

Atzema CL, **Dorian P**, Fang J, Tu JV, Lee DS, Chong AS, Austin PC. A Clinical Decision Instrument for 30-Day Death After an Emergency Department Visit for Atrial Fibrillation: The Atrial Fibrillation in the Emergency Room (AFTER) Study. *Ann Emerg Med.*; 66(6):658-668.e6, 2015.

Webster F, Christian J, Mansfield E, Bhattacharyya O, Hawker G, Levinson W, Naglie G, Pham TN, Rose L, Schull M, Sinha S, Stergiopoulos V, Upshur R, Wilson L; BRIDGES Collaborative.. Capturing the experiences of patients across multiple complex interventions: a meta-qualitative approach. *BMJ Open.*; 5(9):e007664, 2015.

Lip GY, Lanitis T, Mardekian J, Kongnakorn T, Phatak H, **Dorian P**. Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients. *Stroke*. t;46(10):2830-7, 2015.

Moayed Y, Kumareswaran R, **Dorian P**. A 26-year-old competitive soccer player with syncope. *CMAJ*.; 187(16):1225-8, 2015.

Siu AG, Ramadeen A, Hu X, Morikawa L, Zhang L, Lau JY, Liu G, Pop M, Connelly KA, **Dorian P**, Wright GA. Characterization of the ultrashort-TE (UTE) MR collagen signal. *NMR Biomed*.; 28(10):1236-44, 2015.

Lee DS, Hardy J, Yee R, Healey JS, Birnie D, Simpson CS, Crystal E, Mangat I, Nanthakumar K, Wang X, Krahn AD, **Dorian P**, Austin PC, Tu JV; Investigators of the Ontario ICD Database. Clinical Risk Stratification for Primary Prevention Implantable Cardioverter Defibrillators. *Circ Heart Fail*.; 8(5):927-37, 2015.

Ha AC, Singh N, Cox JL, Mancini GB, **Dorian P**, Fournier C, Gladstone DJ, Lockwood E, Shuaib A, Kajil M, Tsigoulis M, Gupta MK. Oral Anticoagulation for Stroke Prevention in Canadian Practice: Stroke Prevention and Rhythm Interventions in Atrial Fibrillation (SPRINT-AF) Registry(.). *Can J Cardiol*.; 32(2):204-10, 2015.

Atzema CL, Austin PC, Chong AS, **Dorian P**, Jackevicius CA. The Long-Term Use of Warfarin Among Atrial Fibrillation Patients Discharged From an Emergency Department With a Warfarin Prescription. *Ann Emerg Med*. t;66(4):347-354.e2, 2015.

Bennell MC, Qiu F, Micieli A, Ko DT, **Dorian P**, Atzema CL, Singh SM, Wijeyesundera HC. Identifying predictors of cumulative healthcare costs in incident atrial fibrillation: a population-based study. *J Am Heart Assoc*.; 4(4). pii: e001684, 2015.

Gladstone DJ, **Dorian P**, Spring M, Panzov V, Mamdani M, Healey JS, Thorpe KE; EMBRACE Steering Committee and Investigators.. Atrial premature beats predict atrial fibrillation in cryptogenic stroke: results from the EMBRACE trial. *Stroke*.; 46(4):936-41, 2015.

Hess PL, Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, Buxton A, Cappato R, **Dorian P**, Hallstrom A, Kadish AH, Kudenchuk PJ, Lee KL, Mark DB, Moss AJ, Steinman R, Inoue LY, Sanders G. Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials. *Circ Cardiovasc Qual Outcomes*.; 8(2):179-86, 2015.

Morrison LJ, Brooks SC, Dainty KN, Dorian P, Needham DM, Ferguson ND, Rubenfeld GD, Slutsky AS, Wax RS, Zwarenstein M, Thorpe K, Zhan C, Scales DC; Strategies for Post-Arrest Care Network.. Improving use of targeted temperature management after out-of-hospital cardiac arrest: a stepped wedge cluster randomized controlled trial. *Crit Care Med*.; 43(5):954-64, 2015.

Dorian P. Whom do you believe? The patient or the ECG? *Heart Rhythm*.; 12(4):666-, 2015.

Aschar-Sobbi R, Izaddoustdar F, Korogyi AS, Wang Q, Farman GP, Yang F, Yang W, Dorian D, Simpson JA, Tuomi JM, Jones DL, Nanthakumar K, Cox B, Wehrens XH, **Dorian P**, Backx

PH. Increased atrial arrhythmia susceptibility induced by intense endurance exercise in mice requires TNF α . *Nat Commun*; 6:6018, 2015.

Pinter A, **Dorian P**. Sudden shortening of the paced AV delay: is this normal pacemaker function? *Neth Heart J*.; 23(2):147-8, 2015.

Pinter A, **Dorian P**. Sudden shortening of the paced AV delay: is this normal pacemaker function? *Neth Heart J*.; 23(2):141-2, 2015.

Idris AH, Guffey D, Pepe PE, Brown SP, Brooks SC, Callaway CW, Christenson J, Davis DP, Daya MR, Gray R, Kudenchuk PJ, Larsen J, Lin S, Menegazzi JJ, Sheehan K, Sopko G, Stiell I, Nichol G, Aufderheide TP; Resuscitation Outcomes Consortium Investigators.. Chest compression rates and survival following out-of-hospital cardiac arrest. *Crit Care Med*.; 43(4):840-8, 2015.

Yu EH, Nair P, Sibbald MG, Lee DS, **Dorian P**. Can diagnostic and procedural skills required to practice cardiology as a specialist be mastered in 3 years? *Can J Cardiol*.; 31(1):91-4, 2015.

Moe GW, Ezekowitz JA, O'Meara E, Lepage S, Howlett JG, Fremes S, Al-Hesayen A, Heckman GA, Abrams H, Ducharme A, Estrella-Holder E, Grzeslo A, Harkness K, Koshman SL, McDonald M, McKelvie R, Rajda M, Rao V, Swiggum E, Virani S, Zieroth S, Arnold JM, Ashton T, D'Astous M, Chan M, De S, **Dorian P**, Giannetti N, Haddad H, Isaac DL, Kouz S, Leblanc MH, Liu P, Ross HJ, Sussex B, White M; Canadian Cardiovascular Society.. The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: anemia, biomarkers, and recent therapeutic trial implications. *Can J Cardiol*.; 31(1):3-16, 2015.

Kumareswaran R, **Dorian P**. Utility of anti-arrhythmic medications in 'lone atrial fibrillation'. *Curr Pharm Des*.; 21(5):573-9. Review. PubMed PMID: 25175095, 2015.

Endrenyi L

Dove ES, Barlas IÖ, Birch K, Boehme C, Borda-Rodriguez A, Byne WM, Chaverneff F, Coşkun Y, Dahl ML, Dereli T, Diwakar S, Elbeyli L, **Endrenyi L**, Eroğlu-Kesim B, Ferguson LR, Güngör K, Gürsoy U, Hekim N, Huzair F, Kaushik K, Kickbusch I, Kiroğlu O, Kolker E, Könönen E, Lin B, Llerena A, Malhan F, Nair B, Patrinos GP, Şardaş S, Sert Ö, Srivastava S, Steuten LM, Toraman C, Vayena E, Wang W, Warnich L, Özdemir V. An Appeal to the Global Health Community for a Tripartite Innovation: An "Essential Diagnostics List," "Health in All Policies," and "See-Through 21(st) Century Science and Ethics". *OMICS J Integrat Biol*.; 19(8):435-42, 2015.

Endrenyi L, Jamali F, Loebenberg R. Subsequent Entry Biologics in Canada: Current State of the Science. *J Pharm Pharm Sci*.; 18(2):177-83, 2015.

Endrenyi L, Chi E, Chow SC, Tothfalusi L. Bioequivalence and biosimilarity of highly variable drugs. *Chinese J Pharm Anal*.; 35(5): 803-11, 2015.

Chow SC, Xu HL, **Endrenyi L**, Song FY. A new scaled criterion for drug interchangeability. *Chinese J. Pharm. Anal.*; 35(5): 844-48, 2015.

Finkelstein Y

Weerdenburg K, **Finkelstein Y**. A 12-year-old girl with seizures after intentional drug overdose. Bupropion overdose. *Pediatr Emerg Care.*; 31(3):217-9, 2015.

Zelner I, Matlow J, Hutson JR, Wax P, Koren G, Brent J, **Finkelstein Y**; Toxicology Investigators Consortium (Toxic). Acute Poisoning During Pregnancy: Observations from the Toxicology Investigators Consortium. *J Med Toxicol.*; 11(3):301-8, 2015.

Finkelstein Y, Macdonald EM, Hollands S, Sivilotti ML, Hutson JR, Mamdani MM, Koren G, Juurlink DN; Canadian Drug Safety and Effectiveness Research Network (CDSERN).. Risk of Suicide Following Deliberate Self-poisoning. *JAMA Psychiatry.*; 72(6):570-5, 2015.

Cole PD, **Finkelstein Y**, Stevenson KE, Blonquist TM, Vijayanathan V, Silverman LB, Neuberg DS, Sallan SE, Robaey P, Waber DP. Polymorphisms in Genes Related to Oxidative Stress Are Associated With Inferior Cognitive Function After Therapy for Childhood Acute Lymphoblastic Leukemia. *J Clin Oncol.*;v33(19):2205-11, 2015.

Simone L, **Finkelstein Y**. The Boy With Kaleidoscope Eyes: A 16 Year Old With Unusual Behaviors. *Pediatr Emerg Care.*; 31(9):677-9, 2015.

Finkelstein Y, Macdonald EM, Hollands S, Hutson JR, Sivilotti ML, Mamdani MM, Koren G, Juurlink DN; Canadian Drug Safety and Effectiveness Research Network (CDSERN).. Long-term outcomes following self-poisoning in adolescents: a population-based cohort study. *Lancet Psychiatry.*; 2(6):532-9, 2015.

Finkelstein Y, Goel G, Hutson JR, Armstrong J, Baum CR, Wax P, Brent J; Toxicology Investigators Consortium (Toxic). Drug Misuse in Adolescents Presenting to the Emergency Department. *Pediatr Emerg Care.* 2015 Oct 13. [Epub ahead of print] PubMed PMID: 26466148.

D. Schnadower, **Y. Finkelstein**, SB. Freedman. Ondansetron and probiotics in the management of pediatric acute gastroenteritis in developed countries. *Current Opinion in Gastroenterology.* 2015 Jan 31(1):1-6.

Y. Finkelstein, G Goel, JR Hutson, J. Armstrong, CR Baum, P Wax, J. Brent. Drug Misuse in Adolescents Presenting to the Emergency Department. **Pediatric Emergency Care.** 2015 October 13 (Epub ahead of print).

L. Simone, Y. Finkelstein. The boy with kaleidoscope eyes. A 16-year old boy with unusual behaviors. **Pediatric Emergency Care.**; 31(9):677-679, 2015.

PD Cole, **Y. Finkelstein**, K.E. Stevenson, T.M. Blonquist, V. Vijayanathan, L.B. Silverman, D.S. Neuberg, S.E. Sallan, P. Robaey, D.P. Waber. Polymorphisms in Genes Related to Oxidative Stress Are Associated with Inferior Cognitive Function after Therapy for Childhood ALL. *Journal of Clinical Oncology*.; 33(19):2205-11, 2015.

Y. Finkelstein, EM. Macdonald, S. Hollands, ML. Sivilotti, JR. Hutson, MM. Mamdani, G. Koren, DN. Juurlink; Canadian Drug Safety and Effectiveness Research Network (CDSERN). Long-term outcomes following self-poisoning in adolescents: A population-based cohort study. *The LANCET Psychiatry*.; 2(6), 532-539, 2015.

Y. Finkelstein, EM. Macdonald, S. Hollands, ML. Sivilotti, JR. Hutson, MM. Mamdani, G. Koren, DN. Juurlink; Canadian Drug Safety and Effectiveness Research Network (CDSERN). Risk of Suicide Following Deliberate Self-poisoning. *JAMA Psychiatry*.; 72(6):570-5, 2015.

George SR

Shen MY, Perreault ML, Bambico FR, Jones-Tabah J, Cheung M, Fan T, **Nobrega JN**, **George SR**. Rapid anti-depressant and anxiolytic actions following dopamine D1-D2 receptor heteromer inactivation. *Eur Neuropsychopharmacol*.; 25(12):2437-48, 2015.

Huroy S, Kanawaty A, Magomedova L, Cummins CL, **George SR**, van der Kooy D, Henderson JT. EphB2 reverse signaling regulates learned opiate tolerance via hippocampal function. *Behav Brain Res*.; 300:85-96, 2015.

Perreault ML, Shen MY, Fan T, **George SR**. Regulation of c-fos expression by the dopamine D1-D2 receptor heteromer. *Neuroscience*. ; 285:194-203, 2015.

Shen MY, Perreault ML, Fan T, **George SR**. The dopamine D1-D2 receptor heteromer exerts a tonic inhibitory effect on the expression of amphetamine-induced locomotor sensitization. *Pharmacol Biochem Behav*.; 128:33-40, 2015.

Goldstein BI

Seleem MA, Merranko JA, Goldstein TR, **Goldstein BI**, Axelson DA, Brent DA, Nimgaonkar VL, Diler RS, Sakolsky DJ, Kupfer DJ, Birmaher B. The longitudinal course of sleep timing and circadian preferences in adults with bipolar disorder. *Bipolar Disord*.; 17(4):392-402, 2015.

Fonseka TM, Tiwari AK, Gonçalves VF, Lieberman JA, Meltzer HY, **Goldstein BI**, Kennedy JL, Kennedy SH, Müller DJ. The role of genetic variation across IL-1 β , IL-2, IL-6, and BDNF in antipsychotic-induced weight gain. *World J Biol Psychiatry*.; 16(1):45-56, 2015.

Siegel RS, Hoepfner B, Yen S, Stout RL, Weinstock LM, Hower HM, Birmaher B, Goldstein TR, **Goldstein BI**, Hunt JI, Strober M, Axelson DA, Gill MK, Keller MB. Longitudinal

associations between interpersonal relationship functioning and mood episode severity in youth with bipolar disorder. *J Nerv Ment Dis.*; 203(3):194-204, 2015.

Goldstein BI, Schaffer A, Wang S, Blanco C. Excessive and premature new-onset cardiovascular disease among adults with bipolar disorder in the US NESARC cohort. *J Clin Psychiatry.*; 76(2):163-9, 2015.

Yen S, Frazier E, Hower H, Weinstock LM, Topor DR, Hunt J, Goldstein TR, **Goldstein BI**, Gill MK, Ryan ND, Strober M, Birmaher B, Keller MB. Borderline personality disorder in transition age youth with bipolar disorder. *Acta Psychiatr Scand.*; 132(4):270-80, 2015.

Shirzadi Z, Crane DE, Robertson AD, Maralani PJ, Aviv RI, Chappell MA, **Goldstein BI**, Black SE, MacIntosh BJ. Automated removal of spurious intermediate cerebral blood flow volumes improves image quality among older patients: A clinical arterial spin labeling investigation. *J Magn Reson Imaging.*; 42(5):1377-85, 2015.

Hatch J, Andreazza A, Olowoyeye O, Rezin GT, Moody A, **Goldstein BI**. Cardiovascular and psychiatric characteristics associated with oxidative stress markers among adolescents with bipolar disorder. *J Psychosom Res.*; 79(3):222-7, 2015.

Newton DF, Naiberg MR, **Goldstein BI**. Oxidative stress and cognition amongst adults without dementia or stroke: Implications for mechanistic and therapeutic research in psychiatric disorders. *Psychiatry Res.*; 227(2-3):127-34, 2015.

Manelis A, Ladouceur CD, Graur S, Monk K, Bonar LK, Hickey MB, Dwojak AC, Axelson D, **Goldstein BI**, Goldstein TR, Bebko G, Bertocci MA, Hafeman DM, Gill MK, Birmaher B, Phillips ML. Altered amygdala-prefrontal response to facial emotion in offspring of parents with bipolar disorder. *Brain.*; 138(Pt 9):2777-90, 2015.

Goldstein BI, Carnethon MR, Matthews KA, McIntyre RS, Miller GE, Raghuvver G, Stoney CM, Wasiak H, McCrindle BW; American Heart Association Atherosclerosis.; Hypertension and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young.. Major Depressive Disorder and Bipolar Disorder Predispose Youth to Accelerated Atherosclerosis and Early Cardiovascular Disease: A Scientific Statement From the American Heart Association. *Circulation.*; 132(10):965-86, 2015.

Levenson JC, Axelson DA, Merranko J, Angulo M, Goldstein TR, Mullin BC, **Goldstein BI**, Brent DA, Diler R, Hickey MB, Monk K, Sakolsky D, Kupfer DJ, Birmaher B. Differences in sleep disturbances among offspring of parents with and without bipolar disorder: association with conversion to bipolar disorder. *Bipolar Disord.*; 17(8):836-48, 2015.

Subramaniapillai M, **Goldstein BI**, MacIntosh BJ, Korczak DJ, Ou X, Scavone A, Arbour-Nicitopoulos K, Faulkner G. Characterizing exercise-induced feelings after one bout of exercise among adolescents with and without bipolar disorder. *J Affect Disord.*; 190:467-73, 2015.

Rosenblat JD, Kakar R, Berk M, Kessing LV, Vinberg M, Baune BT, Mansur RB, Brietzke E, **Goldstein BI**, McIntyre RS. Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis. *Bipolar Disord.*; 18(2):89-101, 2015.

Fonseka TM, Swampillai B, Timmins V, Scavone A, Mitchell R, Collinger KA, **Goldstein BI**. Significance of borderline personality-spectrum symptoms among adolescents with bipolar disorder. *J Affect Disord.*; 170:39-45, 2015.

Hatch J, Collinger K, Moody A, Olowoyeye O, Zhan JQ, **Goldstein BI**. Non-invasive vascular imaging is associated with cardiovascular risk factors among adolescents with bipolar disorder. *Pediatr Cardiol.*; 36(1):158-64, 2015.

Grant DM

Ahmed S, Bott D, Gomez A, Tamblyn L, Rasheed A, Cho T, MacPherson L, Sugamori KS, Yang Y, **Grant DM**, Cummins CL, Matthews J. Loss of the Mono-ADP-ribosyltransferase, Tiparp, Increases Sensitivity to Dioxin-induced Steatohepatitis and Lethality. *J Biol Chem.*; 290(27):16824-40, 2015.

Wang S, Bott D, Tung A, Sugamori KS, **Grant DM**. Relative Contributions of CYP1A2 and CYP2E1 to the Bioactivation and Clearance of 4-Aminobiphenyl in Adult Mice. *Drug Metab Dispos.*; 43(7):916-21, 2015.

Wang S, Sugamori KS, Tung A, McPherson JP, **Grant DM**. N-hydroxylation of 4-aminobiphenyl by CYP2E1 produces oxidative stress in a mouse model of chemically induced liver cancer. *Toxicol Sci.*; 144(2):393-405, 2015.

Hampson DR

Hampson DR, Blatt GJ. Autism spectrum disorders and neuropathology of the cerebellum. *Front Neurosci.*; 9:420, 2015.

Pacey LK, Guan S, Tharmalingam S, Thomsen C, **Hampson DR**. Persistent astrocyte activation in the fragile X mouse cerebellum. *Brain Behav.*; 5(10):e00400, 2015.

Tharmalingam S, Wu C, **Hampson DR**. The calcium-sensing receptor and integrins modulate cerebellar granule cell precursor differentiation and migration. *Dev Neurobiol.*; 76(4):375-89, 2015.

Gholizadeh S, Halder SK, **Hampson DR**. Expression of fragile X mental retardation protein in neurons and glia of the developing and adult mouse brain. *Brain Res.*; 1596:22-30, 2015.

Ellegood J, Anagnostou E, Babineau BA, Crawley JN, Lin L, Genestine M, DiCicco-Bloom E, Lai JK, Foster JA, Peñagarikano O, Geschwind DH, Pacey LK, **Hampson DR**, Laliberté CL,

Mills AA, Tam E, Osborne LR, Kouser M, Espinosa-Becerra F, Xuan Z, Powell CM, Raznahan A, Robins DM, Nakai N, Nakatani J, Takumi T, van Eede MC, Kerr TM, Muller C, Blakely RD, Veenstra-VanderWeele J, Henkelman RM, Lerch JP. Clustering autism: using neuroanatomical differences in 26 mouse models to gain insight into the heterogeneity. *Mol Psychiatry*.; 20(1):118-25, 2015.

Ellegood, E. Anagnostou, B.A. Babineau, J.N. Crawley, L. Lin, M. Genestine, E. DiCicco, D. Bloom, J.K.Y. Lai, J.A. Foster, O. Penagarikano, D.H. Geschwind, L.K. Pacey, **D.R Hampson**, C.L. Laliberte, G. Horev, A.A. Mills, E. Tam, L.R. Osborne, M. Kouser, F. Espinosa Decerra, Z. Xuan, C.M. Powell, A.Raznahan, D.M. Robins, N. Nakai,J. Nakatani, T. Takumi,M.C.van Eede1, T.M. Kerr,C. Muller, R.D.Blakely, J.Veenstra, D VanderWeele, R.M. Henkelman, and J.P.Lerch. Clustering Autism: Using Neuroanatomical Differences in 27 Mouse Models to Gain Insight into the Heterogeneity. *Molecular Psychiatry* (Nature Publishing Group) 20(1), 118-25, 2015.

Gholizadeh S, Halder SK, and **Hampson DR**. Expression of fragile X mental retardation protein in neurons and glia of the developing and adult mouse brain. *Brain Res. Brain Res.* 1596, 22-30, 2015.

Tharmalingam S, Wu C, and **Hampson DR**. The Calcium-sensing Receptor and Integrins Modulate Cerebellar Granule Cell Precursor Differentiation and Migration. *Developmental Neurobiology*, 76(4), 375-389, 2015.

Pacey LKK, Guan A, Tharmalingham S, Thomsen C, and **Hampson DR** (2015) Persistent Astrocyte Activation in the Fragile X Mouse Cerebellum. *Brain and Behavior*.; (10), e00400, 2015.

Hampson DR and Blatt GJ. Autism Spectrum Disorders and Neuropathology of the Cerebellum. *Frontiers in Neuroscience*, published: 06 November 2015

Higgins GA

Zeeb FD, **Higgins GA**, Fletcher PJ. The Serotonin 2C Receptor Agonist Lorcaserin Attenuates Intracranial Self-Stimulation and Blocks the Reward-Enhancing Effects of Nicotine. *ACS Chem Neurosci*.; 6(7):1231-40, 2015.

Higgins GA, Sileniaks LB, Van Niekerk A, Desnoyer J, Patrick A, Lau W, Thevarkunnel S. Enduring attentional deficits in rats treated with a peripheral nerve injury. *Behav Brain Res*.; 286:347-55, 2015.

Higgins GA, Desnoyer J, Van Niekerk A, Sileniaks LB, Lau W, Thevarkunnel S, Izhakova J, DeLannoy IA, Fletcher PJ, DeLay J, Dobson H. Characterization of the 5-HT_{2C} receptor agonist lorcaserin on efficacy and safety measures in a rat model of diet-induced obesity. *Pharmacol Res Perspect*.; 3(1):e00084, 2015.

Higgins GA, Fletcher PJ. Therapeutic Potential of 5-HT_{2C} Receptor Agonists for Addictive Disorders (REVIEW). ACS Chemical Neurosci.; 6: 1071-1088, 2015..

Ito S

van der Plas, E., Nieman, B.J., Butcher, D.T., Hitzler, J.K., Weksberg, R., **Ito, S.** & Schachar, R. Neurocognitive late effects of chemotherapy in survivors of acute lymphoblastic leukemia: focus on Methotrexate. Journal of the Canadian Academy of Child and Adolescent Psychiatry,; 24(1): 25-32, 2015.

Ito S. Children: Are we doing enough? Clin Pharmacol Ther;98:222-224, 2015.

Tanoshima M, Kobayashi T, Tanoshima R, Beyene J, Koren G, **Ito S.** Risks of congenital malformations in offspring exposed to valproic acid in utero: a systematic review and cumulative meta-analysis. Clin Pharmacol Ther.; 98:417-441, 2015.

Shaw K, Amstutz U, Kim RB, Lesko LJ, Turgeon J, Michaud V, Hwang S, **Ito S**, Ross C, Carleton BC; CPNDS Clinical Recommendation Group. Clinical Practice Recommendations on

Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy. Ther Drug Monit.; 37(4):428-436, 2015.

Aminkeng F, Bhavsar AP, Visscher H, Rassekh SR, Li Y, Lee JW, Bruham LR, Caron HN, van Dalen E, Kremer LC, van der Pal H, Amstutz U, Rieder MJ, Bernstein D, Carleton BC, Hayden MR, **Ito S**, Ross, CJD and the Canadian Pharmacogenomics Network for Drug Safety Consortium. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nature Genetics.; 47:1079-1083, 2015.

Kalant H

Kalant H. Cannabis control policy: No rational basis yet for legalization. Clin Pharmacol Ther.; 97(6):538-40, 2015.

Kalant H. Cannabis in the treatment of rheumatic diseases: suggestions for a reasoned approach. J Rheumatol.; 42(2):146-8, 2015.

Kish SJ

Furukawa Y, **Kish SJ.** Parkinsonism in GTP cyclohydrolase 1-deficient DOPA-responsive dystonia. Brain.; 138(Pt 5):e351, 2015.

Payer DE, Guttman M, **Kish SJ**, Tong J, Strafella A, Zack M, Adams JR, Rusjan P, Houle S, Furukawa Y, Wilson AA, Boileau I. [¹¹C]-(+)-PHNO PET imaging of dopamine D(2/3) receptors in Parkinson's disease with impulse control disorders. *Mov Disord.*; 30(2):160-6., 2015.

Boileau I, Tyndale RF, Williams B, Mansouri E, Westwood DJ, Le Foll B, Rusjan PM, Mizrahi R, De Luca V, Zhou Q, Wilson AA, Houle S, **Kish SJ**, Tong J. The fatty acid amide hydrolase C385A variant affects brain binding of the positron emission tomography tracer [¹¹C]CURB. *J Cereb Blood Flow Metab.*; 35(8):1237-40, 2015.

Boileau I, Rusjan PM, Williams B, Mansouri E, Mizrahi R, De Luca V, Johnson DS, Wilson AA, Houle S, **Kish SJ**, Tong J. Blocking of fatty acid amide hydrolase activity with PF-04457845 in human brain: a positron emission tomography study with the novel radioligand [(11)C]CURB. *J Cereb Blood Flow Metab.*; 35(11):1827-35, 2015.

Tong J, Ang LC, Williams B, Furukawa Y, Fitzmaurice P, Guttman M, Boileau I, Hornykiewicz O, **Kish SJ**. Low levels of astroglial markers in Parkinson's disease: relationship to α -synuclein accumulation. *Neurobiol Dis.*; 82:243-53, 2015.

Zack M, Boileau I, Payer D, Chugani B, Lobo DS, Houle S, Wilson AA, Warsh JJ, **Kish SJ**. Differential cardiovascular and hypothalamic pituitary response to amphetamine in male pathological gamblers versus healthy controls. *J Psychopharmacol.*; 29(9):971-82, 2015.

Chiucciariello L, Cooke RG, Miler L, Levitan RD, Baker GB, **Kish SJ**, Kolla NJ, Rusjan PM, Houle S, Wilson AA, Meyer JH. Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors. *Int J Neuropsychopharmacol.*; 19(1). pii: pyv078, 2015.

Boileau I, McCluskey T, Tong J, Furukawa Y, Houle S, **Kish SJ**. Rapid Recovery of Vesicular Dopamine Levels in Methamphetamine Users in Early Abstinence. *Neuropsychopharmacology.*; 41(4):1179-87, 2015.

Payer DE, Park MT, **Kish SJ**, Kolla NJ, Lerch JP, Boileau I, Chakravarty MM. Personality disorder symptomatology is associated with anomalies in striatal and prefrontal morphology. *Front Hum Neurosci.*; 9:472, 2015.

Kotsopoulos J

Gronwald J, Glass K, Rosen B, Karlan B, Tung N, Neuhausen SL, Moller P, Ainsworth P, Sun P, Narod SA, Lubinski J, **Kotsopoulos J**; Hereditary Breast Cancer Clinical Study Group.. Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. *Fertil Steril.*; 105(3):781-5., 2015.

Nikitina D, Chen Z, Vallis K, Poll A, Ainsworth P, Narod SA, **Kotsopoulos J**. Relationship between Caffeine and Levels of DNA Repair and Oxidative Stress in Women with and without a BRCA1 Mutation. *J Nutrigenet Nutrigenomics.*; 8(4-6):174-84, 2015.

Kotsopoulos J, Rosen B, Fan I, Moody J, McLaughlin JR, Risch H, May T, Sun P, Narod SA. Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status. *Gynecol Oncol.*; 140(1):42-7, 2015.

Pettapiece-Phillips R, Kotlyar M, Chehade R, Salmena L, Narod SA, Akbari M, Jurisica I, **Kotsopoulos J**. Uninterrupted Sedentary Behavior Downregulates BRCA1 Gene Expression. *Cancer Prev Res (Phila.)*; 9(1):83-8, 2015.

Kotsopoulos J, Lubinski J, Neuhausen SL, Gronwald J, Lynch HT, Huzarski T, Demsky R, Foulkes WD, Senter L, Friedman S, Ainsworth P, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.. Weight gain after oophorectomy among women with a BRCA1 or BRCA2 mutation. *Womens Health (Lond.)*; 11(4):453-9, 2015.

Iqbal J, Ferdousy T, Dipi R, Salim R, Wu W, Narod SA, **Kotsopoulos J**, Mostafa MG, Ginsburg O. Risk Factors for Premenopausal Breast Cancer in Bangladesh. *Int J Breast Cancer.*; 2015:612042, 2015.

Salmena L, Shaw P, Fans I, McLaughlin, Rosen B, Risch H, Mitchell C, Sun P, Narod SA, **Kotsopoulos J**. Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer. *Eur J Gynaecol Oncol.*; 36(3):260-7, 2015.

Cybulski C, Lubinski J, Huzarski T, Lynch HT, Randall SA, Neuhausen SL, Senter L, Friedman S, Ainsworth P, Singer C, Foulkes WD, Narod SA, Sun P, **Kotsopoulos J**. Prospective

evaluation of alcohol consumption and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Res Treat.*; 151(2):435-41, 2015.

Ivanova A, Loo A, Tworoger S, Crum CP, Fan I, McLaughlin JR, Rosen B, Risch H, Narod SA, **Kotsopoulos J**. Ovarian cancer survival by tumor dominance, a surrogate for site of origin. *Cancer Causes Control.*; 26(4):601-8, 2015.

Nikitina D, Llacuachaqui M, Sepkovic D, Bradlow HL, Narod SA, **Kotsopoulos J**. The effect of oral 3,3'-diindolylmethane supplementation on the 2:16 α -OHE ratio in BRCA1 mutation carriers. *Fam Cancer.*; 14(2):281-6., 2015.

Pettapiece-Phillips R, Narod SA, **Kotsopoulos J**. The role of body size and physical activity on the risk of breast cancer in BRCA mutation carriers. *Cancer Causes Control.*; 26(3):333-44, 2015.

Kotsopoulos J, Shafrir AL, Rice M, Hankinson SE, Eliassen AH, Tworoger SS, Narod SA. The relationship between bilateral oophorectomy and plasma hormone levels in postmenopausal women. *Horm Cancer.*; 6(1):54-63, 2015.

Kotsopoulos J, Lubinski J, Gronwald J, Cybulski C, Demsky R, Neuhausen SL, Kim-Sing C, Tung N, Friedman S, Senter L, Weitzel J, Karlan B, Moller P, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group.. Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. *Int J Cancer.*; 137(5):1136-46, 2015.

Lanca AJ. Migraine. Diagnosis and Therapeutic Advances in Medical and Dental Practice. For Physicians, Pharmacists, Dentists and other Health Care Professionals, U.S.A. Accredited by the American Medical Association, American Dental Association and Academy of General Dentistry. 2015.

Lanctot KL

Intzandt B, Black SE, **Lanctôt KL**, Herrmann N, Oh P, Middleton LE. Is Cardiac Rehabilitation Exercise Feasible for People with Mild Cognitive Impairment? *Can Geriatr J.*; 18(2):65-72., 2015.

Herrmann N, Harimoto T, Balshaw R, **Lanctôt KL**; Canadian Outcomes Study in Dementia (COSID) Investigators.. Risk Factors for Progression of Alzheimer Disease in a Canadian Population: The Canadian Outcomes Study in Dementia (COSID). *Can J Psychiatry.*; 60(4):189-99, 2015.

Eskes GA, **Lanctôt KL**, Herrmann N, Lindsay P, Bayley M, Bouvier L, Dawson D, Egi S, Gilchrist E, Green T, Gubitzi G, Hill MD, Hopper T, Khan A, King A, Kirton A, Moorhouse P, Smith EE, Green J, Foley N, Salter K, Swartz RH; Heart Stroke Foundation Canada Canadian Stroke Best Practices Committees. Canadian Stroke Best Practice Recommendations: Mood, Cognition and Fatigue Following Stroke practice guidelines, update 2015. *Int J Stroke.*; 10(7):1130-40, 2015.

Chau S, Herrmann N, Ruthirakuhan MT, Chen JJ, **Lanctôt KL**. Latrepirdine for Alzheimer's disease. *Cochrane Database Syst Rev.*; (4):CD009524, 2015.

Lai KS, Herrmann N, Saleem M, **Lanctôt KL**. Cognitive Outcomes following Transcatheter Aortic Valve Implantation: A Systematic Review. *Cardiovasc Psychiatry Neurol.*; 2015: 209569.

MacIntosh BJ, Swardfager W, Robertson AD, Tchistiakova E, Saleem M, Oh PI, Herrmann N, Stefanovic B, **Lanctôt KL**. Regional cerebral arterial transit time hemodynamics correlate with vascular risk factors and cognitive function in men with coronary artery disease. *AJNR Am J Neuroradiol.*; 36(2):295-301, 2015.

Santiago C, Herrmann N, Swardfager W, Saleem M, Oh PI, Black SE, **Lanctôt KL**. White Matter Microstructural Integrity Is Associated with Executive Function and Processing Speed in Older Adults with Coronary Artery Disease. *Am J Geriatr Psychiatry.*; 23(7):754-63, 2015.

Swardfager W, Herrmann N, Mazereeuw G, **Lanctôt KL**. Reply to: Serum zinc and the risk of depression in men: observations from a 20-year follow-up study. *Biol Psychiatry.*; 77(3):e13-4. 2015.

Wang DY, Li A, Paes B, Mitchell I, **Lanctôt KL**; CARESS Investigators. First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005-2015). *Eur J Pediatr.*; 176(3):413-422, 2015.

Chau SA, Herrmann N, Eizenman M, Chung J, **Lanctôt KL**. Exploring Visual Selective Attention towards Novel Stimuli in Alzheimer's Disease Patients. *Dement Geriatr Cogn Dis Extra.*; 5(3):492-502, 2015.

Li A, Wang DY, **Lanctôt KL**, Mitchell I, Paes BA; CARESS Investigators. Comparing First- and Second-Year Palivizumab Prophylaxis in Patients with Hemodynamically Significant Congenital Heart Disease in the CARESS Database (2005-2015). *Pediatr Infect Dis J.* 2016 Oct 6. [Epub ahead of print] PubMed PMID: 27753795.

Chan P, Li A, Paes B, Abraha H, Mitchell I, **Lanctôt KL**; CARESS investigators.. Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab. *Pediatr Infect Dis J.*; 34(12):e290-7, 2015.

Mazereeuw G, Herrmann N, Ma DW, Hillyer LM, Oh PI, **Lanctôt KL**. Omega-3/omega-6 fatty acid ratios in different phospholipid classes and depressive symptoms in coronary artery disease patients. *Brain Behav Immun.*; 53:54-8., 2015.

O'Regan J, **Lanctôt KL**, Mazereeuw G, Herrmann N. Cholinesterase inhibitor discontinuation in patients with Alzheimer's disease: a meta-analysis of randomized controlled trials. *J Clin Psychiatry.*; 76(11):e1424-31, 2015.

Mazereeuw G, Herrmann N, Andreazza AC, Khan MM, **Lanctôt KL**. A meta-analysis of lipid peroxidation markers in major depression. *Neuropsychiatr Dis Treat.*; 11:2479-91, 2015.

Herrmann N, O'Regan J, Ruthirakuhan M, Kiss A, Eryavec G, Williams E, Lanctôt KL. A Randomized Placebo-Controlled Discontinuation Study of Cholinesterase Inhibitors in Institutionalized Patients With Moderate to Severe Alzheimer Disease. *J Am Med Dir Assoc.*; 17(2):142-7, 2015.

Abraha HY, **Lanctôt KL**, Paes B. Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention. *Expert Rev Respir Med.*; 9(6):779-99, 2015.

Mazereeuw G, Herrmann N, Xu H, Blanchard AP, Figeys D, Oh PI, Bennett SA, Lanctôt KL. Platelet activating factors are associated with depressive symptoms in coronary artery disease patients: a hypothesis-generating study. *Neuropsychiatr Dis Treat.*; 11:2309-14., 2015.

Saleem M, Herrmann N, Swardfager W, Eisen R, **Lanctôt KL**. Inflammatory Markers in Mild Cognitive Impairment: A Meta-Analysis. *J Alzheimers Dis.*; 47(3):669-79, 2015.

Chen JJ, Chan P, Paes B, Mitchell I, Li A, **Lanctôt KL**; CARESS investigators. Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention. *PLoS One.*; 10(8):e0134711, 2015.

Oremus M, Tarride JE, Pullenayegum E, Clayton N, Mugford G, Godwin M, Huan A, Bacher Y, Villalpando JM, Gill SS, **Lanctôt KL**, Herrmann N; Canadian Willingness-To-Pay Study

Group., Raina P. Caregivers' willingness-to-pay for Alzheimer's disease medications in Canada. *Dementia (London).*; 14(1):63-79, 2015.

Laposa R

Bralha FN, Liyanage SU, Hurren R, Wang X, Son MH, Fung TA, Chingcuanco FB, Tung AY, Andreatza AC, Psarianos P, Schimmer AD, Salmena L, **Laposa RR**. Targeting mitochondrial RNA polymerase in acute myeloid leukemia. *Oncotarget.*; 6(35):37216-28, 2015.

Yeung M, Hurren R, Nemr C, Wang X, Hershenfeld S, Gronda M, Liyanage S, Wu Y, Augustine J, Lee EA, Spagnuolo PA, Southall N, Chen C, Zheng W, Jeyaraju DV, Minden MD, **Laposa RR**, Schimmer AD. Mitochondrial DNA damage by bleomycin induces AML cell death. *Apoptosis.*; 20(6):811-20, 2015.

Le AD

Mantsch JR, Baker DA, Funk D, **Lê AD**, Shaham Y. Stress-Induced Reinstatement of Drug Seeking: 20 Years of Progress. *Neuropsychopharmacology.*; 41(1):335-56, 2015.

Garcia KL, Coen K, Miksys S, **Lê AD**, Tyndale RF. Effect of Brain CYP2B Inhibition on Brain Nicotine Levels and Nicotine Self-Administration. *Neuropsychopharmacology*; 40(8):1910-8, 2015.

Le Foll B

Le Foll B, Tyndale RF. Cannabinoids: Friend or foe? *Clin Pharmacol Ther.*; 97(6):528-31, 2015.

Cluny NL, Keenan CM, Reimer RA, **Le Foll B**, Sharkey KA. Prevention of Diet-Induced Obesity Effects on Body Weight and Gut Microbiota in Mice Treated Chronically with Δ^9 -Tetrahydrocannabinol. *PLoS One.*; 10(12):e0144270, 2015.

Trigo JM, **Le Foll B**. Inhibition of monoacylglycerol lipase (MAGL) enhances cue-induced reinstatement of nicotine-seeking behavior in mice. *Psychopharmacology (Berl).*; 33(10):1815-22, 2015.

Di Ciano P, Guranda M, Lagzdins D, Tyndale RF, Gamaledin I, Selby P, Boileau I, **Le Foll B**. Varenicline-Induced Elevation of Dopamine in Smokers: A Preliminary [(11)C]-(+)-PHNO PET Study. *Neuropsychopharmacology.*; 41(6):1513-20, 2015.

Loheswaran G, Barr MS, Rajji TK, Blumberger DM, **Le Foll B**, Daskalakis ZJ. Alcohol Intoxication by Binge Drinking Impairs Neuroplasticity. *Brain Stimul.*; 9(1):27-32. , 2015.

Di Ciano P, Pushparaj A, Kim A, Hatch J, Masood T, Ramzi A, Khaled MA, Boileau I, Winstanley CA, **Le Foll B**. The Impact of Selective Dopamine D2, D3 and D4 Ligands on the Rat Gambling Task. *PLoS One.*; 10(9):e0136267, 2015.

Sabioni P, Di Ciano P, **Le Foll B**. Effect of a D3 receptor antagonist on context-induced reinstatement of nicotine seeking. *Prog Neuropsychopharmacol Biol Psychiatry.*; 64:149-54, 2015.

Awan S, Samokhvalov AV, Aleem N, Hendershot CS, Irving JA, Kalvik A, Lefebvre L, **Le Foll B**, Quilty L, Voore P. Development and Implementation of an Ambulatory Integrated Care Pathway for Major Depressive Disorder and Alcohol Dependence. *Psychiatr Serv.*; 66(12):1265-7, 2015.

Pushparaj A, **Le Foll B**. Involvement of the caudal granular insular cortex in alcohol self-administration in rats. *Behav Brain Res.*; 293:203-7, 2015.

Le Foll B, Payer D, Di Ciano P, Guranda M, Nakajima S, Tong J, Mansouri E, Wilson AA, Houle S, Meyer JH, Graff-Guerrero A, Boileau I. Occupancy of Dopamine D3 and D2 Receptors by Bupirone: A [11C]-(+)-PHNO PET Study in Humans. *Neuropsychopharmacology.*; 41(2):529-37, 2015.

Sabioni P, Bertram J, **Le Foll B**. Off-Label Use of Medications for Treatment of Benzodiazepine Use Disorder. *Curr Pharm Des.*; 21(23):3306-10, 2015.

Boileau I, Tyndale RF, Williams B, Mansouri E, Westwood DJ, **Le Foll B**, Rusjan PM, Mizrahi R, De Luca V, Zhou Q, Wilson AA, Houle S, Kish SJ, Tong J. The fatty acid amide hydrolase C385A variant affects brain binding of the positron emission tomography tracer [11C]CURB. *J Cereb Blood Flow Metab.* 35(8):1237-40, 2015.

Pushparaj A, Kim AS, Musiol M, Zangen A, Daskalakis ZJ, Zack M, Winstanley CA, **Le Foll B**. Differential Involvement of the Agranular vs Granular Insular Cortex in the Acquisition and Performance of Choice Behavior in a Rodent Gambling Task. *Neuropsychopharmacology.*; 40(12):2832-42, 2015.

Pushparaj A, Kim AS, Musiol M, Trigo JM, **Le Foll B**. Involvement of the rostral agranular insular cortex in nicotine self-administration in rats. *Behav Brain Res.*; 290:77-83, 2015.

15: Loheswaran G, Soklaridis S, Selby P, **Le Foll B**. Screening and Treatment for Alcohol, Tobacco and Opioid Use Disorders: A Survey of Family Physicians across Ontario. *PLoS One.*; 10(4):e0124402, 2015.

Gamaledin IH, Trigo JM, Gueye AB, Zvonok A, Makriyannis A, Goldberg SR, **Le Foll B**. Role of the endogenous cannabinoid system in nicotine addiction: novel insights. *Front Psychiatry.*; 6:41, 2015.

Le Foll B, Ng E, Di Ciano P, Trigo JM. Psychiatric disorders as vulnerability factors for nicotine addiction: what have we learned from animal models? *Curr Top Behav Neurosci.*; 24:155-70, 2015.

Le Strat Y, Dubertret C, **Le Foll B**. Impact of age at onset of cannabis use on cannabis dependence and driving under the influence in the United States. *Accid Anal Prev.*; 76:1-5, 2015.

Le Foll B, Di Ciano P. Neuronal circuitry underlying the impact of D3 receptor ligands in drug addiction. *Eur Neuropsychopharmacol.*; 25(9):1401-9, 2015.

Zai CC, Manchia M, Sønderby IE, Yilmaz Z, De Luca V, Tiwari AK, Squassina A, Zai GC, Shaikh SA, Strauss J, King N, **Le Foll B**, Kaplan AS, Finseth PI, Vaaler AE, Djurovic S, Andreassen OA, Vincent JB, Kennedy JL. Investigation of the genetic interaction between BDNF and DRD3 genes in suicidal behaviour in psychiatric disorders. *World J Biol Psychiatry.*; 16(3):171-9., 2015.

Le Strat Y, **Le Foll B**, Dubertret C. Major depression and suicide attempts in patients with liver disease in the United States. *Liver Int.*; 35(7):1910-6, 2015.

Matthews J

Sarill, M., Zago, M., Shreidan, J.A., Nair, P., **Matthews, J.**, Gomez, A., Hamid, Q., Eidelman, D.H., and Baglole, C.J. The aryl hydrocarbon receptor suppresses cigarette smoke-induced oxidative stress via dioxin response element (DRE)-independent regulation of sulfiredoxin 1. *Free Radical Biology and Medicine* 89:342-357, 2015.

Ahmed, S., Bott, D., Gomez, A., Tamblyn, L., Raheed, A., MacPherson, L., Sugamuri, K.S., Cho, T. Yang, S., Grant, D.M. Cummins, C. and **Matthews, J.** Loss of the Mono-ADP-Ribosyltransferase, TIPARP, increases sensitivity to dioxin-induced steatohepatitis and lethality. *J. Biol. Chem* 290(27):16824-40, 2015.

Bindesbøll, C., Fan, Q., Ruan, H-B., MacPherson, L., Wu, J., Nørgaard, R.C., Steffensen, K.R., Yang, X., **Matthews, J.**, Mandrup, S., Nebb, H.I., Grønning-Wang, L. Liver X Receptor Regulates Hepatic Nuclear O-GlcNAc Cycling and Carbohydrate Responsive Element-Binding Protein Activity. *J of Lipid Res* 56(4):771-85, 2015.

McIntyre RS

Carvalho AF, Köhler CA, **McIntyre RS**, Knöchel C, Brunoni AR, Thase ME, Quevedo J, Fernandes BS, Berk M. Peripheral vascular endothelial growth factor as a novel depression biomarker: A meta-analysis. *Psychoneuroendocrinology.*; 62:18-26, 2015.

Rosenblat JD, **McIntyre RS**. Bipolar Disorder and Inflammation. *Psychiatr Clin North Am.*; 39(1):125-37, 2015.

McIntyre RS, Woldeyohannes HO, Soczynska JK, Maruschak NA, Wium-Andersen IK, Vinberg M, Cha DS, Lee Y, Xiao HX, Gallagher LA, Dale RM, Alsuwaidan MT, Mansur RB, Muzina DJ, Carvalho AF, Jerrell JM, Kennedy SH. Anhedonia and cognitive function in adults with MDD: results from the International Mood Disorders Collaborative Project. *CNS Spectr.*; 21(5):362-366, 2015.

Mansur RB, Rizzo LB, Santos CM, Asevedo E, Cunha GR, Noto MN, Pedrini M, Zeni M, Cordeiro Q, **McIntyre RS**, Brietzke E. Adipokines, metabolic dysfunction and illness course in bipolar disorder. *J Psychiatr Res.*; 74:63-9, 2015.

Kuswanto C, Chin R, Sum MY, Sengupta S, Fagiolini A, **McIntyre RS**, Vieta E, Sim K. Shared and divergent neurocognitive impairments in adult patients with schizophrenia and bipolar disorder: Whither the evidence? *Neurosci Biobehav Rev.*; 61:66-89, 2015.

McIntyre RS, Lee Y, Mansur RB. Treating to target in major depressive disorder: response to remission to functional recovery. *CNS Spectr.*; 20 Suppl 1:20-30; quiz 31, 2015.

McIntyre RS, Fayyad RS, Guico-Pabia CJ, Boucher M. A Post Hoc Analysis of the Effect of Weight on Efficacy in Depressed Patients Treated With Desvenlafaxine 50 mg/d and 100 mg/d. *Prim Care Companion CNS Disord.*; 17(3), 2015.

Hsieh YH, Chiu WC, Lin CF, Chan HL, Liang HY, Lee Y, **McIntyre RS**, Chen VC. Antidepressants and Gastric Cancer: A Nationwide Population-Based Nested Case-Control Study. *PLoS One.*; 10(11):e0143668, 2015.

Woldeyohannes HO, Soczynska JK, Maruschak NA, Syeda K, Wium-Andersen IK, Lee Y, Cha DS, Xiao HX, Gallagher LA, Dale RM, Alsuwaidan MT, Mansur RB, Muzina DJ, Carvalho AF, Jerrell J, Kennedy S, **McIntyre RS**. Binge eating in adults with mood disorders: Results from the International Mood Disorders Collaborative Project. *Obes Res Clin Pract.*; 10(5):531-543, 2015.

Chan HL, Hsieh YH, Lin CF, Liang HY, Huang KY, Chiu WC, Lee Y, **McIntyre RS**, Chen VC. Invasive Cervical Cancer and Antidepressants: A Nationwide Population-Based Study. *Medicine (Baltimore).*; 94(42):e1866, 2015.

Landbloom RL, Mackle M, Wu X, Kelly L, Snow-Adami L, **McIntyre RS**, Mathews M, Hundt C. Asenapine: Efficacy and safety of 5 and 10mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar I disorder. *J Affect Disord.*; 190:103-10, 2015.

McIntyre RS, Gorwood P, Thase ME, Liss C, Desai D, Chen J, Bauer M. Early Symptom Improvement as a Predictor of Response to Extended Release Quetiapine in Major Depressive Disorder. *J Clin Psychopharmacol.*; 35(6):706-10, 2015.

Bortolato B, Carvalho AF, Soczynska JK, Perini GI, **McIntyre RS**. The Involvement of TNF- α in Cognitive Dysfunction Associated with Major Depressive Disorder: An Opportunity for Domain Specific Treatments. *Curr Neuropharmacol.*; 13(5):558-76, 2015.

Carvalho AF, **McIntyre RS**. Translational Perspectives in Treatment-Resistant Mood Disorders. *Curr Neuropharmacol.*; 13(5):556-7, 2015.

Köhler CA, Carvalho AF, Alves GS, **McIntyre RS**, Hyphantis TN, Cammarota M. Autobiographical Memory Disturbances in Depression: A Novel Therapeutic Target? *Neural Plast.*; 2015:759139, 2015.

Freitas TH, Hyphantis TN, Andreoulakis E, Quevedo J, Miranda HL, Alves GS, Souza MH, Braga LL, Pargament KI, Soczynska JK, **McIntyre RS**, Carvalho AF. Religious coping and its influence on psychological distress, medication adherence, and quality of life in inflammatory bowel disease. *Rev Bras Psiquiatr.*; 37(3):219-27, 2015.

Kudlow PA, Rosenblat JD, Weissman CR, Cha DS, Kakar R, **McIntyre RS**, Sharma V. Prevalence of fibromyalgia and co-morbid bipolar disorder: A systematic review and meta-analysis. *J Affect Disord.*; 188:134-42, 2015.

Rosenblat JD, Brietzke E, Mansur RB, Maruschak NA, Lee Y, **McIntyre RS**. Inflammation as a neurobiological substrate of cognitive impairment in bipolar disorder: Evidence, pathophysiology and treatment implications. *J Affect Disord.*; 188:149-59, 2015.

Rizvi SJ, Sproule BA, Gallaughier L, **McIntyre RS**, Kennedy SH. Correlates of benzodiazepine use in major depressive disorder: The effect of anhedonia. *J Affect Disord.*; 187:101-5, 2015.

McIntyre RS, Xiao HX, Syeda K, Vinberg M, Carvalho AF, Mansur RB, Maruschak N, Cha DS. The prevalence, measurement, and treatment of the cognitive dimension/domain in major depressive disorder. *CNS Drugs.*; 29(7):577-89, 2015.

Birner A, Seiler S, Lackner N, Bengesser SA, Queissner R, Fellendorf FT, Platzer M, Ropele S, Enzinger C, Schwingenschuh P, Mangge H, Pirpamer L, Deutschmann H, **McIntyre RS**, Kapfhammer HP, Reininghaus B, Reininghaus EZ. Cerebral White Matter Lesions and Affective Episodes Correlate in Male Individuals with Bipolar Disorder. *PLoS One.*; 10(8):e0135313, 2015.

Rosenblat JD, Kakar R, **McIntyre RS**. The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. *Int J Neuropsychopharmacol.*; 19(2). pii: pyv082, 2015.

McIntyre RS. Evidence-Based Treatment of Bipolar Disorder, Bipolar Depression, and Mixed Features. *J Fam Pract.*; 64(6 Suppl):S16-23, 2015.

McIntyre RS, Fayyad RS, Guico-Pabia CJ, Boucher M. An Analysis of Relapse Rates and Predictors of Relapse in 2 Randomized, Placebo-Controlled Trials of Desvenlafaxine for Major Depressive Disorder. *Prim Care Companion CNS Disord.*; 17(1), 2015.

Fonseka TM, **McIntyre RS**, Soczynska JK, Kennedy SH. Evidence to support peripheral and central IL-6 signaling targets to treat depression. *Expert Opin Investig Drugs*. 24(7):991-2, 2015.

Lackner N, Bengesser SA, Birner A, Painold A, Fellendorf FT, Platzer M, Reininghaus B, Weiss EM, Mangge H, **McIntyre RS**, Fuchs D, Kapfhammer HP, Wallner-Liebmann SJ, Reininghaus EZ. Abdominal obesity is associated with impaired cognitive function in euthymic bipolar individuals. *World J Biol Psychiatry*. t;17(7):535-46, 2015.

Al-Sukhni M, Maruschak NA, **McIntyre RS**. Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. *Expert Opin Drug Saf*. 14(8):1291-304, 2015.

McIntyre RS, Weiller E. Real-world determinants of adjunctive antipsychotic prescribing for patients with major depressive disorder and inadequate response to antidepressants: a case review study. *Adv Ther*.; 32(5):429-44, 2015.

Kessing LV, Vradi E, **McIntyre RS**, Andersen PK. Causes of decreased life expectancy over the life span in bipolar disorder. *J Affect Disord*.; 180:142-7, 2015.

Rizvi SJ, Cyriac A, Grima E, Tan M, Lin P, Gallagher LA, **McIntyre RS**, Kennedy SH. Depression and employment status in primary and tertiary care settings. *Can J Psychiatry*.; 60(1):14-22, 2015.

McIntyre RS, Cucchiaro J, Pikalov A, Kroger H, Loebel A. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. *J Clin Psychiatry*.; 76(4):398-405, 2015.

Nierenberg AA, **McIntyre RS**, Sachs GS. Improving outcomes in patients with bipolar depression: a comprehensive review. *J Clin Psychiatry*.; 76(3):e10, 2015.

Rosenblat JD, **McIntyre RS**. Are medical comorbid conditions of bipolar disorder due to immune dysfunction? *Acta Psychiatr Scand*.; 132(3):180-91, 2015.

Fonseka TM, **McIntyre RS**, Soczynska JK, Kennedy SH. Novel investigational drugs targeting IL-6 signaling for the treatment of depression. *Expert Opin Investig Drugs*. r;24(4):459-75, 2015.

Mansur RB, Brietzke E, **McIntyre RS**. Is there a "metabolic-mood syndrome"? A review of the relationship between obesity and mood disorders. *Neurosci Biobehav Rev*.; 52:89-104, 2015.

Bengesser SA, Lackner N, Birner A, Fellendorf FT, Platzer M, Mitteregger A, Unterweger R, Reininghaus B, Mangge H, Wallner-Liebmann SJ, Zelzer S, Fuchs D, **McIntyre RS**, Kapfhammer HP, Reininghaus EZ. Peripheral markers of oxidative stress and antioxidative defense in euthymia of bipolar disorder--Gender and obesity effects. *J Affect Disord*.; 172:367-74, 2015.

Carvalho AF, Takwoingi Y, Sales PM, Soczynska JK, Köhler CA, Freitas TH, Quevedo J, Hyphantis TN, **McIntyre RS**, Vieta E. Screening for bipolar spectrum disorders: A comprehensive meta-analysis of accuracy studies. *J Affect Disord.*; 172:337-46, 2015.

McIntyre RS, Soczynska JK, Cha DS, Woldeyohannes HO, Dale RS, Alsuwaidan MT, Gallagher LA, Mansur RB, Muzina DJ, Carvalho A, Kennedy SH. The prevalence and illness characteristics of DSM-5-defined "mixed feature specifier" in adults with major depressive disorder and bipolar disorder: Results from the International Mood Disorders Collaborative Project. *J Affect Disord.*; 172:259-64, 2015.

Reininghaus EZ, Lackner N, Fellendorf FT, Bengesser S, Birner A, Reininghaus B, Unterweger R, Platzer M, Wallner-Liebmann SJ, Zelzer S, Mangge H, Fuchs D, Kapfhammer HP, **McIntyre RS**. Weight cycling in bipolar disorder. *J Affect Disord.*; 171:33-8, 2015.

McIntyre RS, Soczynska JZ, Woldeyohannes HO, Alsuwaidan MT, Cha DS, Carvalho AF, Jerrell JM, Dale RM, Gallagher LA, Muzina DJ, Kennedy SH. The impact of cognitive impairment on perceived workforce performance: results from the International Mood Disorders Collaborative Project. *Compr Psychiatry.*; 279-82, 2015.

Lackner N, Mangge H, Reininghaus EZ, **McIntyre RS**, Bengesser SA, Birner A, Reininghaus B, Kapfhammer HP, Wallner-Liebmann SJ. Body fat distribution and associations with metabolic and clinical characteristics in bipolar individuals. *Eur Arch Psychiatry Clin Neurosci.*; 265(4):313-9, 2015.

Takayanagi Y, Spira AP, **McIntyre RS**, Eaton WW. Sex hormone binding globulin and verbal memory in older men. *Am J Geriatr Psychiatry.*; 23(3):253-60, 2015.

McPherson JP

Wang S, Sugamori KS, Tung A, **McPherson JP**, Grant DM. N-hydroxylation of 4-aminobiphenyl by CYP2E1 produces oxidative stress in a mouse model of chemically induced liver cancer. *Toxicol Sci.*; 144(2):393-405, 2015.

Milgram NW

Snigdha S, de Rivera C, **Milgram NW**, Cotman CW. Effect of mitochondrial cofactors and antioxidants supplementation on cognition in the aged canine. *Neurobiol Aging.*; 37:171-8, 2015.

Landsberg GM, Beck A, Lopez A, Deniaud M, Araujo JA, **Milgram NW**. Dog-appeasing pheromone collars reduce sound-induced fear and anxiety in beagle dogs: a placebo-controlled study. *Vet Rec.*; 177(10):260, 2105.

Lazarowski L, Foster ML, Gruen ME, Sherman BL, Fish RE, **Milgram NW**, Dorman DC.

Olfactory discrimination and generalization of ammonium nitrate and structurally related odorants in Labrador retrievers. *Anim Cogn.*; 18(6):1255-65, 2015.

Mitchell J

Robinson KA, Ou WL, Guan X, Sugamori KS, Bandyopadhyay A, Ernst OP, **Mitchell J**. The effect of phosphorylation on arrestin-rhodopsin interaction in the squid visual system. *J Neurochem.* 135:1129-1139, 2015.

Mittmann N

Raju RS, Coburn N, Liu N, Porter JM, Seung SJ, Cheung MC, Goyert N, Leighl NB, Hoch JS, Trudeau ME, Evans WK, Dainty KN, Earle CC, **Mittmann N**. A population-based study of the epidemiology of pancreatic cancer: a brief report. *Curr Oncol.*; 22(6):e478-84, 2015.

Mittmann N, Stout NK, Lee P, Tosteson AN, Trentham-Dietz A, Alagoz O, Yaffe MJ. Total cost-effectiveness of mammography screening strategies. *Health Rep.*; 26(12):16-25, 2015.

Yaffe MJ, **Mittmann N**, Lee P, Tosteson AN, Trentham-Dietz A, Alagoz O, Stout NK. Clinical outcomes of modelling mammography screening strategies. *Health Rep.*; 26(12):9-15, 2015.

Yaffe MJ, **Mittmann N**, Lee P, Tosteson AN, Trentham-Dietz A, Alagoz O, Stout NK. Modelling mammography screening for breast cancer in the Canadian context: Modification and testing of a microsimulation model. *Health Rep.*; 26(12):3-8, 2015.

Mittmann N, Seung SJ, Cheng SY, Liu N, Camacho X, Maclagan L, DeAngelis C, Earle C. Generating Costing Algorithms For Oncology Drugs Using Administrative Databases. *Value Health.*; 18(7):A691, 2015.

Mittmann N, Hassan S, Seung SJ, Saherawala H, Hoffstein V, Bradley-Kennedy C. Examining Health System And Resource Utilization And Medical Management Of Patients Idiopathic Pulmonary Fibrosis In Ontario: A Preliminary Analysis. *Value Health.*; 18(7):A499, 2015.

Seung SJ, Cheng SY, Rahman F, Earle C, **Mittmann N**. Quantifying Costs of Medical Personnel Involved with Radiation therapy Using Administrative Databases. *Value Health.*; 18(7):A477, 2015.

Mittmann N, Hassan S, Patel J, Tinmouth J. Cost-Effectiveness Of Directly Mailed Fobt Kits To Previous Responders Being Recalled For Screening. *Value Health.*; 18(7):A458, 2015.

Cheung MC, Earle CC, Rangrej J, Ho TH, Liu N, Barbera L, Saskin R, Porter J, Seung SJ, **Mittmann N**. Impact of aggressive management and palliative care on cancer costs in the final month of life. *Cancer.*; 121(18):3307-15, 2015.

Tseng E, Prica A, Zhang L, **Mittmann N**, Seung SJ, Callum J, Kim T, Wells RA, Buckstein R. Monthly blood transfusions decrease after four months of azacitidine. *Vox Sang.*; 109(2):163-7, 2015.

Heelan K, Hitzig SL, Knowles S, Drucker AM, **Mittmann N**, Walsh S, Shear NH. Loss of Work Productivity and Quality of Life in Patients With Autoimmune Bullous Dermatoses. *J Cutan Med Surg.*; 19(6):546-54, 2015.

Cheung MC, Hay AE, Crump M, Imrie KR, Song Y, Hassan S, Risebrough N, Sussman J, Couban S, MacDonald D, Kukreti V, Kouroukis CT, Baetz T, Szwajcer D, Desjardins P, Shepherd L, Meyer RM, Le A, Chen BE, **Mittmann N**; Committee on Economic Analysis and the Hematology Disease Site Committee, NCIC Clinical Trials Group. Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12. *J Natl Cancer Inst.*; 107(7). pii: djv106, 2015.

Nanwa N, Kendzerska T, Krahn M, Kwong JC, Daneman N, Witteman W, **Mittmann N**, Cadarette SM, Rosella L, Sander B. The economic impact of Clostridium difficile infection: a systematic review. *Am J Gastroenterol.*; 110(4):511-9, 2015.

Heelan K, Hassan S, Bannon G, Knowles S, Walsh S, Shear NH, **Mittmann N**. Cost and Resource Use of Pemphigus and Pemphigoid Disorders Pre- and Post-Rituximab. *J Cutan Med Surg.*; 19(3):274-82, 2015.

Kuthubutheen J, **Mittmann N**, Amoodi H, Qian W, Chen JM. The effect of different utility measures on the cost-effectiveness of bilateral cochlear implantation. *Laryngoscope.*; 125(2):442-7, 2015

Woo KY, Keast D, Parsons N, Sibbald RG, **Mittmann N**. The cost of wound debridement: a Canadian perspective. *Int Wound J.*; 12(4):402-7, 2015.

Lien K, Tam VC, Ko YJ, **Mittmann N**, Cheung MC, Chan KK. Impact of country-specific EQ-5D-3L tariffs on the economic value of systemic therapies used in the treatment of metastatic pancreatic cancer. *Curr Oncol.*; 22(6):e443-52, 2015.

Rueda S, Smith P, Bekele T, O'Brien K, Husbands W, Li A, Jose-Boerbridge M, **Mittmann N**, Rachlis A, Conyers L, Boomer KB, Rourke SB; ECHO Study Team.. Is any job better than no job? Labor market experiences and depressive symptoms in people living with HIV. *AIDS Care.*; 27(7):907-15, 2015.

Rocker GM, Verma JY, Demmons J, **Mittmann N**. Number Needed To... \$ave? *Clin Invest Med.* 2015; 38(1):E11-4. PubMed PMID: 25662619.

Mizrahi R

Parker CA, Rabiner EA, Gunn RN, Searle G, Martarello L, Comley RA, Davy M, Wilson AA, Houle S, **Mizrahi R**, Laruelle M, Cunningham VJ. Human Kinetic Modeling of the 5HT6 PET Radioligand 11C-GSK215083 and Its Utility for Determining Occupancy at Both 5HT6 and 5HT2A Receptors by SB742457 as a Potential Therapeutic Mechanism of Action in Alzheimer Disease. *J Nucl Med.*; 56(12):1901-9, 2015.

Koshimori Y, Ko JH, **Mizrahi R**, Rusjan P, Mabrouk R, Jacobs MF, Christopher L, Hamani C, Lang AE, Wilson AA, Houle S, Strafella AP. Imaging Striatal Microglial Activation in Patients with Parkinson's Disease. *PLoS One.*; 10(9):e0138721, 2015.

Mizrahi R. Social Stress and Psychosis Risk: Common Neurochemical Substrates? *Neuropsychopharmacology.*; 41(3):666-74, 2015.

Boileau I, Rusjan PM, Williams B, Mansouri E, **Mizrahi R**, De Luca V, Johnson DS, Wilson AA, Houle S, Kish SJ, Tong J. Blocking of fatty acid amide hydrolase activity with PF-04457845 in human brain: a positron emission tomography study with the novel radioligand [(11C)CURB. *J Cereb Blood Flow Metab.*; 35(11):1827-35, 2015.

Boileau I, Tyndale RF, Williams B, Mansouri E, Westwood DJ, Le Foll B, Rusjan PM, **Mizrahi R**, De Luca V, Zhou Q, Wilson AA, Houle S, Kish SJ, Tong J. The fatty acid amide hydrolase C385A variant affects brain binding of the positron emission tomography tracer [11C]CURB. *J Cereb Blood Flow Metab.*; 35(8):1237-40, 2015.

Suridjan I, Pollock BG, Verhoeff NP, Voineskos AN, Chow T, Rusjan PM, Lobaugh NJ, Houle S, Mulsant BH, **Mizrahi R**. In-vivo imaging of grey and white matter neuroinflammation in Alzheimer's disease: a positron emission tomography study with a novel radioligand, [18F]-FEPPA. *Mol Psychiatry.*; 20(12):1579-87, 2015.

Setiawan E, Wilson AA, **Mizrahi R**, Rusjan PM, Miler L, Rajkowska G, Suridjan I, Kennedy JL, Rekkas PV, Houle S, Meyer JH. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. *JAMA Psychiatry.*; 72(3):268-75, 2015.

Kenk M, Selvanathan T, Rao N, Suridjan I, Rusjan P, Remington G, Meyer JH, Wilson AA, Houle S, **Mizrahi R**. Imaging neuroinflammation in gray and white matter in schizophrenia: an in-vivo PET study with [18F]-FEPPA. *Schizophr Bull.*; 41(1):85-93, 2015.

Koshimori Y, Segura B, Christopher L, Lobaugh N, Duff-Canning S, **Mizrahi R**, Hamani C, Lang AE, Aminian K, Houle S, Strafella AP. Imaging changes associated with cognitive abnormalities in Parkinson's disease. *Brain Struct Funct.*; 220(4):2249-61., 2015.

Müller DJ

Schmack K, Rössler H, Sekutowicz M, Brandl EJ, **Müller DJ**, Petrovic P, Sterzer P. Linking unfounded beliefs to genetic dopamine availability. *Front Hum Neurosci.*; 9:521, 2015.

Hicks JK, Bishop JR, Sangkuhl K, **Müller DJ**, Ji Y, Leckband SG, Leeder JS, Graham RL, Chiulli DL, Llerena A, Skaar TC, Scott SA, Stingl JC, Klein TE, Caudle KE, Gaedigk A. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. *Clin Pharmacol Ther.*; 98: 127-134, 2015. PMID: 25974703

Todd RM, Ehlers MR, Müller DJ, Robertson A, Palombo DJ, Freeman N, Levine B, Anderson AK. Neurogenetic variations in norepinephrine availability enhance perceptual vividness. *J Neurosci.*; 35: 6506-6516, 2015.

Walden LM, Brandl EJ, Changasi A, Sturgess JE, Soibel A, Notario JFD, Cheema S, Braganza N, Marshe VS, Freeman N, Tiwari AK, Kennedy JL, **Müller DJ**. Physicians' opinions following pharmacogenetic testing for psychotropic medication. *Psychiatry Res.*; 229: 913-918, 2015.

Carlier N, Marshe VS, Cmorejova J, Davis C, **Müller DJ**. Genetic similarities between compulsive overeating and addiction phenotypes: A case for “Food Addiction”? *Curr Psychiatry Rep.*; 17:96, 2015.

Srirenakumar V, Huang E, **Müller DJ**. Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: An update. *Expert Opin. Drug Metab. Toxicol.*; 11: 1709-1731, 2015.

Fonseka TM, Tiwari AK, Gonçalves VF, Lieberman JA, Meltzer HY, Goldstein BI, Kennedy JL, Kennedy SH, **Müller DJ**. The role of genetic variation across IL-1alpha, IL-2, IL-6 and BDNF in antipsychotic-induced weight gain. *World J Biol Psychiatry.*; 16 (1), 45-56, 2015.

Shams TA, Foussias G, Zawadzki JA, Marshe VS, Siddiqui I, **Müller DJ**, Wong AH. The effects of video games on cognition and brain structure: Potential implications for neuropsychiatric disorders. *Curr Psychiatry Rep.*; 17: 609, 2015.

Pouget JG, Gonçalves VF, Nurmi EL, P Laughlin C, Mallya KS, McCracken JT, Aman MG, McDougle CJ, Scahill L, Misener VL, Tiwari AK, Zai CC, Brandl EJ, Felsky D, Leung AQ, Lieberman JA, Meltzer HY, Potkin SG, Niedling C, Steimer W, Leucht S, Knight J, **Müller DJ**, Kennedy JL. Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes. *Pharmacogenomics.*; 16: 5-22, 2015.

Brandl EJ, Chowdhury N, Tiwari AK, Lett TA, Meltzer HY, Kennedy JL, **Müller DJ**. Genetic variation in CYP3A43 gene is associated with response to antipsychotic medication. *Journal of Neural Transmission.*; 122: 29-34, 2015.

Zai G, Tiwari AK, Chowdhury NI, Brandl EJ, Shaikh SA, Freeman N, Lieberman JA, Meltzer HY, **Müller DJ**, Kennedy JL. (shared senior-authorship). Association study of GABA(A) alpha2 receptor subunit gene variants in antipsychotic-induced weight gain. *J Clin Psychopharmacol* .; 35: 7-12, 2015.

Neuman MG

Neuman MG, Cohen L, Opris M, Nanau RM, Hyunjin J. Hepatotoxicity of Pyrrolizidine Alkaloids. *J Pharm Pharm Sci.*; 18(4):825-43, 2015.

Neuman MG, Maor Y, Nanau RM, Melzer E, Mell H, Opris M, Cohen L, Malnick S. Alcoholic Liver Disease: Role of Cytokines. *Biomolecules.*; 5(3):2023-34, 2015.

Neuman MG, Malnick S, Maor Y, Nanau RM, Melzer E, Ferenci P, Seitz HK, Mueller S, Mell H, Samuel D, Cohen LB, Kharbanda KK, Osna NA, Ganesan M, Thompson KJ, McKillop IH, Bautista A, Bataller R, French SW. Alcoholic liver disease: Clinical and translational research. *Exp Mol Pathol.*; 99(3):596-610, 2015.

Neuman MG, Cohen LB, Nanau RM. Hyaluronic acid as a non-invasive biomarker of liver fibrosis. *Clin Biochem.*; 49(3):302-15, 2015.

Nanau RM, **Neuman MG**. Biomolecules and Biomarkers Used in Diagnosis of Alcohol Drinking and in Monitoring Therapeutic Interventions. *Biomolecules.*; 5(3):1339-85, 2015.

Neuman MG, Nanau RM, Cohen LB. Nonmedicinal interventions in non-alcoholic fatty liver disease. *Can J Gastroenterol Hepatol.*; 29(5):241-52, 2015.

Neuman MG, Cohen LB, Nanau RM. Quinolones-induced hypersensitivity reactions. *Clin Biochem.*; 48(10-11):716-39, 2015.

Neuman MG, Nanau RM, Oruña-Sánchez L, Coto G. Hyaluronic acid and wound healing. *J Pharm Pharm Sci.*; 18(1):53-60, 2015.

Nobrega JN

Bambico FR, Bregman T, Diwan M, Li J, Darvish-Ghane S, Li Z, Laver B, Amorim BO, Covolan L, **Nobrega JN**, Hamani C. Neuroplasticity-dependent and –independent mechanisms of chronic deep brain stimulation in stressed rats. *Transl Psychiatry.*; 5:e674, 2015.

Shen MY, Perreault ML, Bambico FR, Jones-Tabah J, Cheung M, Fan T, **Nobrega JN**, George SR. Rapid anti-depressant and anxiolytic actions following dopamine D1-D2 receptor heteromer inactivation. *Eur Neuropsychopharmacol.*; 25(12):2437-48., 2015.

Nona CN, Bermejo MK, Ramsey AJ, **Nobrega JN**. Changes in dendritic spine density in the nucleus accumbens do not underlie ethanol sensitization. *Synapse.*; 69(12):607-10, 2015.

Amorim BO, Covolan L, Ferreira E, Brito JG, Nunes DP, de Moraes DG, **Nobrega JN**, Rodrigues AM, deAlmeida AC, Hamani C. Deep brain stimulation induces antiapoptotic and anti-inflammatory effects in epileptic rats. *J Neuroinflammation.*; 12:162, 2015.

Winter C, Bregman T, Voget M, Raymond R, Hadar R, **Nobrega JN**, Hamani C. Acute high frequency stimulation of the prefrontal cortex or nucleus accumbens does not increase hippocampal neurogenesis in rats. *J Psychiatr Res.*; 68:27-9, 2015.

Visanji NP, Kamali Sarvestani I, Creed MC, Shams Shoaie Z, **Nobrega JN**, Hamani C, Hazrati LN. Deep brain stimulation of the subthalamic nucleus preferentially alters the translational profile of striatopallidal neurons in an animal model of Parkinson's disease. *Front Cell Neurosci.*; 9:221, 2015.

Insel N, Pilkiw M, **Nobrega JN**, Hutchison WD, Takehara-Nishiuchi K, Hamani C. Chronic deep brain stimulation of the rat ventral medial prefrontal cortex disrupts hippocampal-prefrontal coherence. *Exp Neurol.*; 269:1-7, 2015.

Bregman T, Reznikov R, Diwan M, Raymond R, Butson CR, **Nobrega JN**, Hamani C. Antidepressant-like Effects of Medial Forebrain Bundle Deep Brain Stimulation in Rats are not Associated With Accumbens Dopamine Release. *Brain Stimul.*; 8(4):708-13, 2015.

Lister J, Fletcher PJ, **Nobrega JN**, Remington G. Behavioral effects of food-derived opioid-like peptides in rodents: Implications for schizophrenia? *Pharmacol Biochem Behav.*; 134:70-8, 2015.

Reznikov R, Diwan M, **Nobrega JN**, Hamani C. Towards a better preclinical model of PTSD: characterizing animals with weak extinction, maladaptive stress responses and low plasma corticosterone. *J Psychiatr Res.*; 61:158-65, 2015.

McCormick PN, Fletcher PJ, Wilson VS, Browne JD, **Nobrega JN**, Remington GJ. Low dose pramipexole causes D3 receptor-independent reduction of locomotion and responding for a conditioned reinforcer. *Neuropharmacology.*; 89:225-31, 2015.

Lobo DS, Aleksandrova L, Knight J, Casey DM, el-Guebaly N, **Nobrega JN**, Kennedy JL. Addiction-related genes in gambling disorders: new insights from parallel human and pre-clinical models. *Mol Psychiatry.*; 20(8):1002-10, 2015.

Nona CN, Creed MC, Hamani C, **Nobrega JN**. Effects of high-frequency stimulation of the nucleus accumbens on the development and expression of ethanol sensitization in mice. *Behav Pharmacol.*; 26(1-2):184-92, 2015.

Nulman I

Terrana N, Koren G, Pivovarov J, Etwel F, **Nulman I**. Pregnancy outcomes following in-utero exposure to second generation antipsychotics: a systematic review and meta-analysis. *J Biol Psychiatry*; 35 (5):559-65, 2015.

Kaplan YC, **Nulman I**, Koren, G. Dose-Dependent Risk of Malformations With Antiepileptic Drugs: An Analysis of Data From the EURAP Epilepsy and Pregnancy Registry.; 37(5):557-8, 2015.

Nulman I, Koren G, Rovet J, Barrera M, Streiner DL, Feldman M. Neurodevelopment of Children Prenatally Exposed to Selective Reuptake Inhibitor Antidepressants: Toronto Sibling Study. *J Clin Psychiatry*;; 76(7):e842–e847, 2015.

Kaplan YC, Ozsarfaty J, Nickel C, **Nulman I**, Koren G. Pregnancy Outcome Following First Trimester Exposure to Topical Retinoids: A Systematic Review and Meta-Analysis. *The British Journal of Dermatology*; 173 (5):1132-1141, 2015.

Marchenko A, Etwel F, Olukayode O, Nickel C, Koren G, **Nulman I**. Pregnancy Outcome Following Prenatal Exposure to Triptan Medications: A Meta-Analysis. *Headache: The Journal of Head and Face Pain.*; 55 (4): 490-501, 2015.

Nulman I, Terrana N, Lutwak M, Pearlston M. Psychotropic Medications in Pregnancy. In S. Macleod, S. Hill, G. Koren & A. Rane (eds.), *Optimizing Treatment for Children in the Developing World*. Springer International Publishing.: 291-302, 2015.

Brandlistuen RE, Ystrom E, **Nulman I**, Koren G, Nordeng H. Re: Letter to the Editor: Annotations and Reflections Response to “Pregnancy and Paracetamol: Methodological Considerations on the Study of Associations between In Utero Exposure to Drugs and Childhood Neurodevelopment”. *Basic & Clinical Pharmacology & Toxicology.*; 16(1): 6-8, 2015.

Brandlistuen RE, Ystrom E, Eberhard-Gran M, Nulman I, Koren G, Nordeng H. Behavioural effects of fetal antidepressant exposure in a Norwegian cohort of discordant siblings. *Int J Epidemiol.*; 44(4):1397-407, 2015.

Nylen K

Ng R, Maxwell CJ, Yates EA, Nylen K, Antflick J, Jette N. Brain disorders in Ontario: prevalence, incidence and costs from health administrative data. ICES Publication, 2015.

Warrick N, Brown A and Nylen K. The critical and complex challenge of dementia: Why governments must use big data to respond to the challenges of dementia. In: Anderson, G. and J. Oderkirk (eds.), *Dementia Research and Care: Can Big Data Help?* OECD Publishing, Paris, 2015.

Okey AB

Houlahan KE, Prokopec SD, Sun RX, Moffat ID, Lindén J, Lensu S, **Okey AB**, Pohjanvirta R, Boutros PC. Transcriptional profiling of rat white adipose tissue response to 2,3,7,8-tetrachlorodibenzo-p-dioxin. *Toxicol Appl Pharmacol.*; 288(2):223-31, 2015.

Houlahan KE, Prokopec SD, Moffat ID, Lindén J, Lensu S, **Okey AB**, Pohjanvirta R, Boutros PC. Transcriptional profiling of rat hypothalamus response to 2,3,7,8-tetrachlorodibenzo-p-dioxin. *Toxicology.*; 328:93-101, 2015.

Pace-Asciak CR

Pace-Asciak CR. Pathophysiology of the hepoxilins. *Biochim Biophys Acta.*; 1851(4):383-96, 2015.

Douda D, Grasemann H, **Pace-Asciak CR** and Palaniyar N. A lipid mediator Hepoxilin A3 is a natural inducer of neutrophil extracellular traps in human neutrophils. *Mediators in Inflammation*

special issue "New Developments in Cystic Fibrosis Airway Inflammation", Online publication - Volume 2015, Article ID 520871.

Pang KS

Pang KS, Yang QJ. Response to letter to the editor on "fractional clearance for verapamil N-demethylation in the isolated rat liver preparation". *Drug Metab Dispos.*; 43(7):1058-9, 2015.

Quach HP, Yang QJ, Chow EC, Mager DE, Hoi SY, **Pang KS**. PKPD modelling to predict altered disposition of 1 α ,25-dihydroxyvitamin D3 in mice due to dose-dependent regulation of CYP27B1 on synthesis and CYP24A1 on degradation. *Br J Pharmacol.*; 172(14):3611-26, 2015.

Yang QJ, Jerath A, Bies RR, Wasowicz M, **Pang KS**. Pharmacokinetic modeling of tranexamic acid for patients undergoing cardiac surgery with normal renal function and model simulations for patients with renal impairment. *Biopharm Drug Dispos.*; 36(5):294-307, 2015.

Yang QJ, Si L, Tang H, Sveigaard HH, Chow EC, **Pang KS**. PBPK modeling to unravel nonlinear pharmacokinetics of verapamil to estimate the fractional clearance for verapamil N-demethylation in the recirculating rat liver preparation. *Drug Metab Dispos.*; 43(4):631-45, 2015.

Varma MV, **Pang KS**, Isoherranen N, Zhao P. Dealing with the complex drug-drug interactions: towards mechanistic models. *Biopharm Drug Dispos.*; 36(2):71-92, 2015.

Durk MR, Fan J, Sun H, Yang Y, Pang H, **Pang KS**, de Lannoy IA. Vitamin D receptor activation induces P-glycoprotein and increases brain efflux of quinidine: an intracerebral microdialysis study in conscious rats. *Pharm Res.*;32(3):1128-40, 2015.

Parker JD

Cotter G, Davison BA, Milo O, Bourge RC, Cleland JG, Jondeau G, Krum H, O'Connor CM, Metra M, **Parker JD**, Torre-Amione G, van Veldhuisen DJ, Kobrin I, Rainisio M, Senger S, Edwards C, McMurray JJ, Teerlink JR; VERITAS Investigators.. Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS. *J Card Fail.*; 22(10):815-22, 2015.

McLaughlin K, Drewlo S, **Parker JD**, Kingdom JC. Current Theories on the Prevention of Severe Preeclampsia With Low-Molecular Weight Heparin. *Hypertension.*; 66(6):1098-103, 2015.

Parker JD. Therapeutic developments in the therapy of heart failure: lessons to be learned. *Eur Heart J.*; 36(30):1952-4, 2015.

Kwong W, Liuni A, Zhou K, **Parker JD**. Cyclooxygenase inhibition and rosuvastatin-induced vascular protection in the setting of ischemia-reperfusion: A human in vivo study. *Vascul Pharmacol.*; 71:159-65, 2015.

Metra M, Cotter G, El-Khorazaty J, Davison BA, Milo O, Carubelli V, Bourge RC, Cleland JG, Jondeau G, Krum H, O'Connor CM, **Parker JD**, Torre-Amione G, van Veldhuisen DJ, Rainisio M, Kobrin I, McMurray JJ, Teerlink JR. Acute heart failure in the elderly: differences in clinical characteristics, outcomes, and prognostic factors in the VERITAS Study. *J Card Fail.*; 21(3):179-88, 2015.

Petronis A

Pal M, Ebrahimi S, Oh G, Khare T, Zhang A, Kaminsky ZA, Wang SC, **Petronis A**. High Precision DNA Modification Analysis of HCG9 in Major Psychosis. *Schizophr Bull.*; 42(1):170-7, 2015.

Oh G, Wang SC, Pal M, Chen ZF, Khare T, Tochigi M, Ng C, Yang YA, Kwan A, Kaminsky ZA, Mill J, Gunasinghe C, Tackett JL, Gottesman II, Willemsen G, de Geus EJ, Vink JM,

Slagboom PE, Wray NR, Heath AC, Montgomery GW, Turecki G, Martin NG, Boomsma DI, McGuffin P, Kustra R, **Petronis A**. DNA modification study of major depressive disorder: beyond locus-by-locus comparisons. *Biol Psychiatry.*; 77(3):246-55, 2015.

Pollock RA, Thavaneswaran A, Pellett F, Chandran V, **Petronis A**, Rahman P, Gladman DD. Further Evidence Supporting a Parent-of-Origin Effect in Psoriatic Disease. *Arthritis Care Res (Hoboken)*.; 67(11):1586-90, 2015.

Pollock BG

Gerretsen P, Menon M, Chakravarty MM, Lerch JP, Mamo DC, Remington G, **Pollock BG**, Graff Guerrero A: Illness Denial in Schizophrenia Spectrum Disorders: A Function of Left Hemisphere Dominance. *Human Brain Mapp*: 36(1):213-25, 2015.

Tsuboi T, Suzuki T, Bies RR, Remington G, **Pollock BG**, Mimura M, Uchida H. Challenging the Need for Sustained Blockade of Dopamine D2 Receptor Estimated from Antipsychotic

Plasma Levels in the Maintenance Treatment of Schizophrenia: A Single-Blind, Randomized, Controlled Study. *Schizophr Res*: 164(1-3):149-54, 2015.

Rajji TK, Mulsant BH, Davies S, Kalache SM, Tsoutsoulas C, **Pollock BG**, Remington G: Prediction of working memory performance in schizophrenia by plasma ratio of clozapine to N-desmethylclozapine. *Am J Psychiatry*: 172(6):579-85, 2015.

Graff-Guerrero A, Rajji TK, Mulsant BH, Nakajima S, Caravaggio F, Suzuki T, Uchida H, Gerretsen P, Mar W, **Pollock BG**, Mamo DC: Maintenance Antipsychotic Dose Can Be Decreased in Late-life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study with [¹¹C]-raclopride. *JAMA Psychiatry*: 72(9):927-34, 2015.

Davies SJC, Mulsant BH, Flint AJ, Meyers BS, Rothschild AJ, Whyte EM, Kirshner MM, Sorisio D, **Pollock BG**, Bies RR for the STOP-PD study group: The Impact of Sertraline Co-

Administration on the Pharmacokinetics of Olanzapine: a Population Pharmacokinetic Analysis of the STOP-PD Study. *Clin Pharmacokinet*: 54(11):1161-8, 2015.

Weintraub D, Drye LT, Porsteinsson AP, Rosenberg PB, **Pollock BG**, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Schneider LS, Shade DM, Yesavage J, Lyketsos CG, for the CitAD Research Group: Time to response to citalopram treatment for agitation in Alzheimer disease. *Am J Geriatr Psychiatry*: 23(11):1127-33, 2015.

Rosenberg PB, Drye LT, Porsteinsson AP, **Pollock BG**, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Schneider LS, Shade DM, Weintraub D, Newell J, Yesavage J, Lyketsos CG for the CitAD Research Group: Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial. *Int Psychogeriatr*: 27(12):2059-67, 2015.

Tsuboi T, Bies RR, Suzuki T, Takeuchi H, Nakajima S, Graff-Guerrero A, Mamo DC, Caravaggio F, Plitman E, Mimura M, **Pollock BG**, Uchida H: Predicting Plasma Olanzapine

Concentration Following a Change in Dosage: A Population Pharmacokinetic Study. *Pharmacopsychiatry*; 48(7):286-291, 2015.

Suridjan I, **Pollock BG**, Verhoeff NP, Voineskos AN, Chow T, Rusjan PM, Lobaugh NJ, Houle S, Mulsant BH, Mizrahi R: In-vivo imaging of grey and white matter neuroinflammation in Alzheimer's disease: a Positron emission tomography study with a novel radioligand, [18F]-FEPPA. *Molecular Psychiatry*; 20(12):1579-87, 2015.

Ramsey AJ

Nona CN, Bermejo MK, **Ramsey AJ**, Nobrega JN. Changes in dendritic spine density in the nucleus accumbens do not underlie ethanol sensitization. *Synapse*.; 69(12):607-10, 2015.

Masoud ST, Vecchio LM, Bergeron Y, Hossain MM, Nguyen LT, Bermejo MK, Kile B, Sotnikova TD, Siesser WB, Gainetdinov RR, Wightman RM, Caron MG, Richardson JR, Miller GW, **Ramsey AJ**, Cyr M, Salahpour A. Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits. *Neurobiol Dis.*; 74:66-75, 2015.

Ruddy RM, Chen Y, Milenkovic M, **Ramsey AJ**. Differential effects of NMDA receptor antagonism on spine density. *Synapse*.; 69(1):52-6, 2015.

Ross RA

Alexander SP, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Southan C, Buneman OP, Catterall WA, Cidlowski JA, Davenport AP, Fabbro D, Fan G, McGrath JC, Spedding M, Davies JA; CGTP Collaborators. The Concise Guide to PHARMACOLOGY 2015/16: Overview. *Br J Pharmacol.*; 172(24):5729-43, 2015.

Drew JE, Farquharson AJ, Vase H, Carey FA, Steele RJ, **Ross RA**, Bunton DC. Molecular Profiling of Multiplexed Gene Markers to Assess Viability of Ex Vivo Human Colon Explant Cultures. *Biores Open Access.* ;4(1):425-30, 2015.

Mounsey RB, Mustafa S, Robinson L, **Ross RA**, Riedel G, Pertwee RG, Teismann P. Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. *Exp Neurol.*; 273:36-44, 2015.

Ignatowska-Jankowska BM, Baillie GL, Kinsey S, Crowe M, Ghosh S, Owens RA, Damaj IM, Poklis J, Wiley JL, Zanda M, Zanato C, Greig IR, Lichtman AH, **Ross RA**. A Cannabinoid CB1

Receptor-Positive Allosteric Modulator Reduces Neuropathic Pain in the Mouse with No Psychoactive Effects. *Neuropsychopharmacology.*; 40(13):2948-59, 2015.

Bolognini D, **Ross RA**. Medical cannabis vs. synthetic cannabinoids: What does the future hold? Clin Pharmacol Ther; 97(6):568-70, 2015.

Poklis JL, Clay DJ, Ignatowska-Jankowska BM, Zanato C, **Ross RA**, Greig IR, Abdullah RA, Mustafa MA, Lichtman AH, Poklis A. HPLC-MS-MS Determination of ZCZ-011, A Novel Pharmacological Tool for Investigation of the Cannabinoid Receptor in Mouse Brain Using Clean Screen FASt™ Column Extraction. J Anal Toxicol. ;39(5):353-8, 2015.

Roy PJ

Burns AR, Luciani GM, Musso G, Bagg R, Yeo M, Zhang Y, Rajendran L, Glavin J, Hunter R, Redman E, Stasiuk S, Schertzberg M, McQuibban GA, Caffrey CR, Cutler R, Tyers M, Giaever G, Nislow C, Fraser AG, MacRae CA, Gilleard J and **Roy PJ**. *Caenorhabditis elegans* is a useful model for Anthelmintic Discovery. Nature Communications. 6:7485, 2015.

Chan K, Seetharaman A, Selman G and **Roy PJ**. Immunoprecipitation of Proteins in *Caenorhabditis elegans*. Bioprotocol 5(7), 2015.

Salahpour A

Lam VM, Espinoza S, Gerasimov AS, Gainetdinov RR, **Salahpour A**. In-vivo pharmacology of Trace-Amine Associated Receptor 1. Eur J Pharmacol.; 763(Pt B):136-42, 2015.

Lohr KM, Stout KA, Dunn AR, Wang M, **Salahpour A**, Guillot TS, Miller GW. Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity. ACS Chem Neurosci.; 6(5):790-9, 2015.

Beerepoot P, Lam VM, Salahpour A. A β -lactamase based assay to measure surface expression of membrane proteins. Methods Mol Biol.; 1270:107-14, 2015.

Masoud ST, Vecchio LM, Bergeron Y, Hossain MM, Nguyen LT, Bermejo MK, Kile B, Sotnikova TD, Siesser WB, Gainetdinov RR, Wightman RM, Caron MG, Richardson JR, Miller GW, Ramsey AJ, Cyr M, **Salahpour A**. Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits. Neurobiol Dis.; 74:66-75, 2015.

Salmena L

Bralha FN, Liyanage SU, Hurren R, Wang X, Son MH, Fung TA, Chingcuanco FB, Tung AY, Andreatza AC, Psarianos P, Schimmer AD, **Salmena L**, Laposa RR. Targeting mitochondrial RNA polymerase in acute myeloid leukemia. Oncotarget.; 6(35):37216-28, 2015.

Salmena L, Shaw P, Fans I, McLaughlin, Rosen B, Risch H, Mitchell C, Sun P, Narod SA, Kotsopoulos J. Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer. *Eur J Gynaecol Oncol.*; 36(3):260-7, 2015.

Woolley JF, Dzneladze I, Salmena L. Phosphoinositide signaling in cancer: INPP4B Akt(s) out. *Trends Mol Med.*; 21(9):530-2, 2015.

Li Chew C, Lunardi A, Gulluni F, Ruan DT, Chen M, **Salmena L**, Nishino M, Papa A, Ng C, Fung J, Clohessy JG, Sasaki J, Sasaki T, Bronson RT, Hirsch E, Pandolfi PP. In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes. *Cancer Discov.*; 5(7):740-51, 2015.

Dzneladze I, He R, Woolley JF, Son MH, Sharobim MH, Greenberg SA, Gabra M, Langlois C, Rashid A, Hakem A, Ibrahimova N, Arruda A, Löwenberg B, Valk PJ, Minden MD, **Salmena L**. INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia. *Leukemia.*; 29(7):1485-95, 2015.

Schapira M

Schapira M. *Science. Structural Biology. Chromatin complex, crystal clear* 16.10.2015 350(6258):278-9, 2015.

Kaniskan HÜ, Szewczyk MM, Yu Z, Eram MS, Yang X, Schmidt K, Luo X, Dai M, He F, Zang I, Lin Y, Kennedy S, Li F, Dobrovetsky E, Dong A, Smil D, Min SJ, Landon M, Lin-Jones J, Huang XP, Roth BL, **Schapira M**, Atadja P, Barsyte-Lovejoy D, Arrowsmith CH, Brown PJ, Zhao K, Jin J, Vedadi M. A potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3). *Angew Chem Int Ed Engl.*; 54(17):5166-70, 2015.

Xu C, Liu K, Ahmed H, Loppnau P, **Schapira M**, Min J. Structural Basis for the Discriminative Recognition of N6-Methyladenosine RNA by the Human YT521-B Homology Domain Family of Proteins. *J Biol Chem.*; 290(41):24902-13, 2015.

Huston A, Arrowsmith CH, Knapp S, **Schapira M**. Probing the epigenome. *Nat Chem Biol.*; 11(8):542-5, 2015.

Arrowsmith CH, Audia JE, Austin C, Baell J, Bennett J, Blagg J, Bountra C, Brennan PE, Brown PJ, Bunnage ME, Buser-Doepner C, Campbell RM, Carter AJ, Cohen P, Copeland RA, Cravatt B, Dahlin JL, Dhanak D, Edwards AM, Frederiksen M, Frye SV, Gray N, Grimshaw CE, Hepworth D, Howe T, Huber KV, Jin J, Knapp S, Kotz JD, Kruger RG, Lowe D, Mader MM, Marsden B, Mueller-Fahrnow A, Müller S, O'Hagan RC, Overington JP, Owen DR, Rosenberg SH, Roth B, Ross R, **Schapira M**, Schreiber SL, Shoichet B, Sundström M, Superti-Furga G, Taunton J, Toledo-Sherman L, Walpole C, Walters MA, Willson TM, Workman P, Young RN, Zuercher WJ. The promise and peril of chemical probes. *Nat Chem Biol.*; 11(8):536-41. Erratum in: *Nat Chem Biol.*; 11(11):887. *Nat Chem Biol.*; 11(8):541. Roth, Brian [Corrected to

Roth, Bryan] and Frederiksen, Mathias [Added]. PubMed PMID: 26196764; PubMed Central PMCID: PMC4706458, 2015.

Grebien F, Vedadi M, Getlik M, Giambruno R, Grover A, Avellino R, Skucha A, Vittori S, Kuznetsova E, Smil D, Barsyte-Lovejoy D, Li F, Poda G, **Schapira M**, Wu H, Dong A, Senisterra G, Stukalov A, Huber KV, Schönegger A, Marcellus R, Bilban M, Bock C, Brown PJ, Zuber J, Bennett KL, Al-Awar R, Delwel R, Nerlov C, Arrowsmith CH, Superti-Furga G. Pharmacological targeting of the Wdr5-MLL interaction in C/EBP α N-terminal leukemia. *Nat Chem Biol.*; 11(8):571-8, 2015.

Eram MS, Kuznetsova E, Li F, Lima-Fernandes E, Kennedy S, Chau I, Arrowsmith CH, **Schapira M**, Vedadi M. Kinetic characterization of human histone H3 lysine 36 methyltransferases, ASH1L and SETD2. *Biochim Biophys Acta.*; 1850(9):1842-8, 2015.

Cabaye A, Nguyen KT, Liu L, Pande V, **Schapira M**. Structural diversity of the epigenetics pocketome. *Proteins.*; 83(7):1316-26, 2015.

Smil D, Eram MS, Li F, Kennedy S, Szewczyk MM, Brown PJ, Barsyte-Lovejoy D, Arrowsmith CH, Vedadi M, **Schapira M**. Discovery of a Dual PRMT5-PRMT7 Inhibitor. *ACS Med Chem Lett.*; 6(4):408-12., 2015.

Schimmer BP

Schimmer BP. Sixteenth conference on the adrenal cortex (Adrenal 2014), Chicago, Illinois, June 17-20, 2014. *Mol Cell Endocrinol.*; 408:1, 2015.

Schimmer BP, Cordova M. Corticotropin (ACTH) regulates alternative RNAsplicing in Y1 mouse adrenocortical tumor cells. *Mol Cell Endocrinol.*; 408:5-11, 2015.

Seeman P

Seeman P. Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors. *Synapse.*; 69(4):183-9, 2015.

Semple JW

Guo L, Kapur R, Aslam R, Speck ER, Zufferey A, Zhao Y, Kim M, Lazarus AH, Ni H, **Semple JW**. CD20+ B-cell depletion therapy suppresses murine CD8+T-cell-mediated immune thrombocytopenia. *Blood.*; 127(6):735-8., 2015.

Aslam R, Segel GB, Burack R, Spence SA, Speck ER, Guo L, **Semple JW**. Splenic lymphocyte subtypes in immune thrombocytopenia: increased presence of a subtype of B-regulatory cells. *Br J Haematol.*; 173(1):159-60, 2015.

Kapur R, Zufferey A, Boilard E, **Semple JW**. Nouvelle cuisine: platelets served with inflammation. *J Immunol*. 194(12):5579-87, 2015.

Semple JW. C-reactive protein boosts antibody-mediated platelet destruction. *Blood*.; 125(11):1690-1, 2015.

Setnik B

Setnik B, Roland CL, Goli V, Pixton GC, Levy-Cooperman N, Smith I, Webster L. Self-reports of prescription opioid abuse and diversion among recreational opioid users in a Canadian and a United States city. *J Opioid Manag.*; 11(6):463-73, 2015.

Setnik B, Bramson C, Bass A, Levy-Cooperman N, Malhotra B, Matschke K, Sommerville KW, Wolfram G, Geoffroy P. Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): A randomized, controlled abuse-potential study in nondependent recreational opioid users. *J Clin Pharmacol.*; 55(12):1351-61, 2015.

Setnik B, Roland CL, Sommerville KW, Pixton GC, Berke R, Calkins A, Goli V. A multicenter, primary care-based, open-label study to identify behaviors related to prescription opioid misuse, abuse, and diversion in opioid-experienced patients with chronic moderate-to-severe pain. *J Pain Res.*; 8:361-73, 2015.

Setnik B, Roland CL, Sommerville KW, Pixton GC, Berke R, Calkins A, Goli V. A multicenter, primary-care-based, open-label study to assess the success of converting opioid-experienced patients with chronic moderate-to-severe pain to morphine sulfate and naltrexone hydrochloride extended-release capsules using a standardized conversion guide. *J Pain Res.*; 8:347-60, 2015.

Rauck RL, Hale ME, Bass A, Bramson C, Pixton G, Wilson JG, **Setnik B**, Meisner P, Sommerville KW, Malhotra BK, Wolfram G. A randomized double-blind, placebo-controlled efficacy and safety study of ALO-02 (extended-release oxycodone surrounding sequestered naltrexone) for moderate-to-severe chronic low back pain treatment. *Pain.*; 156(9):1660-9, 2015.

Shear NH

Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, **Shear NH**. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Update. *Am J Clin Dermatol.*; 16(6):475-93, 2015.

Dodiuk-Gad RP, Olteanu C, Jeschke MG, Cartotto R, Fish J, **Shear NH**. Treatment of toxic epidermal necrolysis in North America. *J Am Acad Dermatol.*; 73(5):876-7.e2, 2015.

Alhusayen R, **Shear NH**. Scientific evidence for the use of current traditional systemic therapies in patients with hidradenitis suppurativa. *J Am Acad Dermatol.*; 73(5 Suppl 1):S42-6, 2015.

Shaw K, Amstutz U, Kim RB, Lesko LJ, Turgeon J, Michaud V, Hwang S, Ito S, Ross C, Carleton BC; CPNDS Clinical Recommendation Group.. Clinical Practice Recommendations on

Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy. *Ther Drug Monit.*; 37(4):428-36, 2015.

Dodiuk-Gad RP, **Shear NH**. Granulomatous Drug Eruptions. *Dermatol Clin.*; 33(3):525-39, 2015.

Heelan K, Hitzig SL, Knowles S, Drucker AM, Mittmann N, Walsh S, **Shear NH**. Loss of Work Productivity and Quality of Life in Patients With Autoimmune Bullous Dermatoses. *J Cutan Med Surg.*; 19(6):546-54, 2015.

Heelan K, Mahar AL, Walsh S, **Shear NH**. Pemphigus and associated comorbidities: a cross-sectional study. *Clin Exp Dermatol.*; 40(6):593-9, 2015.

Heelan K, Hassan S, Bannon G, Knowles S, Walsh S, **Shear NH**, Mittmann N. Cost and Resource Use of Pemphigus and Pemphigoid Disorders Pre- and Post-Rituximab. *J Cutan Med Surg.*; 19(3):274-82, 2015.

Dodiuk-Gad RP, Ish-Shalom S, **Shear NH**. Systemic glucocorticoids: important issues and practical guidelines for the dermatologist. *Int J Dermatol.*; 54(6):723-9, 2015.

Laws PM, Heelan K, Al-Mohammed F, Walsh S, **Shear NH**. Pemphigus herpetiformis: a case series and review of the literature. *Int J Dermatol.*; 54(9):1014-22, 2015.

Shram MJ

Shram MJ, Cohen-Barak O, Chakraborty B, Bassan M, Schoedel KA, Hallak H, Eyal E, Weiss S, Gilgun-Serki Y, Sellers EM, Faulknor J, Spiegelstein O. J Clin Psychopharmacol. Assessment of Pharmacokinetic and Pharmacodynamic Interactions Between Albumin-Fused Mutated Butyrylcholinesterase and Intravenously Administered Cocaine in Recreational Cocaine Users.; 35(4):396-405, 2015.

Reches A, Nir RR, **Shram MJ**, Dickman D, Laufer I, Shani-Hershkovich R, Stern Y, Weiss M, Yarnitsky D, Geva AB. A novel electroencephalography-based tool for objective assessment of network dynamics activated by nociceptive stimuli. *Eur J Pain.*; 20(2):250-62, 2015.

Shram MJ, Silverman B, Ehrich E, Sellers EM, Turncliff R. Use of Remifentanyl in a Novel Clinical Paradigm to Characterize Onset and Duration of Opioid Blockade by Samidorphan, a Potent μ -Receptor Antagonist. *J Clin Psychopharmacol.* 35(3):242-9, 2015.

Sibille E

Seney ML, Tripp A, McCune S, Lewis DA, **Sibille E**. Laminar and cellular analyses of reduced somatostatin gene expression in the subgenual anterior cingulate cortex in major depression. *Neurobiol Dis.*; 73:213-9, 2015.

Lin LC, **Sibille E**. Somatostatin, neuronal vulnerability and behavioral emotionality. *Mol Psychiatry*.; 20(3):377-87, 2015.

Lin LC, **Sibille E**. Transcriptome changes induced by chronic psychosocial/environmental or neuroendocrine stressors reveal a selective cellular vulnerability of cortical somatostatin (SST) neurons, compared with pyramidal (PYR) neurons. *Mol Psychiatry*.; 20(3):285, 2015.

Lin CW, Chang LC, Tseng GC, Kirkwood CM, **Sibille EL**, Sweet RA. VSNL1 Co-Expression Networks in Aging Include Calcium Signaling, Synaptic Plasticity, and Alzheimer's Disease Pathways. *Front Psychiatry*.; 6:30, 2015.

Bassi S, Seney ML, Argibay P, **Sibille E**. Elevated Hippocampal Cholinergic Neurostimulating Peptide precursor protein (HCNP-pp) mRNA in the amygdala in major depression. *J Psychiatr Resr* ;63:105-16, 2015.

McKinney BC, Lin CW, Oh H, Tseng GC, Lewis DA, **Sibille E**. Hypermethylation of BDNF and SST Genes in the Orbital Frontal Cortex of Older Individuals: A Putative Mechanism for Declining Gene Expression with Age. *Neuropsychopharmacology*.; 40(11):2604-13, 2015.

Pabba M, **Sibille E**. Sigma-1 and N-Methyl-d-Aspartate Receptors: A Partnership with Beneficial Outcomes. *Mol Neuropsychiatry*.; 1(1):47-51, 2015.

Ding Y, Chang LC, Wang X, Guilloux JP, Parrish J, Oh H, French BJ, Lewis DA, Tseng GC, **Sibille E**. Molecular and Genetic Characterization of Depression: Overlap with other Psychiatric Disorders and Aging. *Mol Neuropsychiatry*.; 1(1):1-12, 2015.

Nikolova YS, Iruku SP, Lin CW, Conley ED, Puralewski R, French B, Hariri AR, **Sibille E**. FRAS1-related extracellular matrix 3 (FREM3) single-nucleotide polymorphism effects on gene expression, amygdala reactivity and perceptual processing speed: An accelerated aging pathway of depression risk. *Front Psychol*.; 6:1377, 2015.

Snead OC III

Cortez MA, Kostopoulos GK, **Snead OC 3rd**. Acute and chronic pharmacological models of generalized absence seizures. *J Neurosci Methods*.; 260:175-84, 2015.

Ibrahim GM, Morgan BR, Smith ML, Kerr E, Donner E, Go CY, Doesburg S, Taylor M, Widjaja E, Rutka JT, **Snead OC 3rd**. Thalamocortical connectivity is enhanced following functional hemispherotomy for intractable lateralized epilepsy. *Epilepsy Behav*.; 51:281-5, 2015.

Jones K, Go C, Boyd J, Ochi A, McCoy B, Puka K, **Snead OC 3rd**. Vigabatrin as First-Line Treatment for Infantile Spasms Not Related to Tuberous Sclerosis Complex. *Pediatr Neurol*.; 53(2):141-5, 2015.

Okanari K, Baba S, Otsubo H, Widjaja E, Sakuma S, Go CY, Jones KC, Nishioka K, Oba S, Matsui T, Ueno M, Ukitsu S, Rutka JT, Drake JM, Donner EJ, Weiss SK, **Snead OC 3rd**, Ochi A. Rapid eye movement sleep reveals epileptogenic spikes for resective surgery in children with generalized interictal discharges. *Epilepsia.*; 56(9):1445-53, 2015.

Dorfer C, Ochi A, **Snead OC 3rd**, Donner E, Holowka S, Widjaja E, Rutka JT. Functional hemispherectomy for catastrophic epilepsy in very young infants: technical considerations and complication avoidance. *Childs Nerv Syst.*; 31(11):2103-9, 2015.

Blichowski M, Shephard A, Armstrong J, Shen L, Cortez MA, Eubanks JH, **Snead OC 3rd**. The GIRK2 subunit is involved in IS-like seizures induced by GABA(B) receptor agonists. *Epilepsia.*; 56(7):1081-7, 2015.

Limotai C, Go CY, Baba S, Okanari K, Ochi A, Rutka JT, **Snead OC 3rd**, Otsubo H. Steal phenomenon in Sturge-Weber syndrome imitating an ictal electroencephalography change in the contralateral hemisphere: report of 2 cases. *J Neurosurg Pediatr.*; 16(2):212-6, 2015.

Mercimek-Mahmutoglu S, Patel J, Cordeiro D, Hewson S, Callen D, Donner EJ, Hahn CD, Kannu P, Kobayashi J, Minassian BA, Moharir M, Siriwardena K, Weiss SK, Weksberg R, **Snead OC 3rd**. Diagnostic yield of genetic testing in epileptic encephalopathy in childhood. *Epilepsia.*; 56(5):707-16, 2015.

Ibrahim GM, Morgan BR, Doesburg SM, Taylor MJ, Pang EW, Donner E, Go CY, Rutka JT, **Snead OC 3rd**. Atypical language laterality is associated with large-scale disruption of network integration in children with intractable focal epilepsy. *Cortex.*; 65:83-8, 2015.

Todorovski Z, Asrar S, Liu J, Saw NM, Joshi K, Cortez MA, **Snead OC 3rd**, Xie W, Jia Z. LIMK1 regulates long-term memory and synaptic plasticity via the transcriptional factor CREB. *Mol Cell Biol.*; 35(8):1316-28, 2015.

Akiyama T, Akiyama M, Kobayashi K, Okanishi T, Boelman CG, Nita DA, Ochi A, Go CY, **Snead OC 3rd**, Rutka JT, Drake JM, Chuang S, Otsubo H. Spatial relationship between fast and slow components of ictal activities and interictal epileptiform discharges in epileptic spasms. *Clin Neurophysiol.*; 126(9):1684-91, 2015.

Jones K, **Snead OC 3rd**, Boyd J, Go C. Adrenocorticotrophic hormone versus prednisolone in the treatment of infantile spasms post vigabatrin failure. *J Child Neurol.*; 30(5):595-600, 2015.

Mohammadi M, Okanishi T, Okanari K, Baba S, Sumiyoshi H, Sakuma S, Ochi A, Widjaja E, Go CY, **Snead OC 3rd**, Otsubo H. Asymmetrical generalized paroxysmal fast activities in children with intractable localization-related epilepsy. *Brain Dev.*; 37(1):59-65, 2015.

Widjaja E, Go C, McCoy B, Snead OC. Neurodevelopmental outcome of infantile spasms: A systematic review and meta-analysis. *Epilepsy Res.*; 109:155-62, 2015.

Fallah A, Rodgers SD, Weil AG, Vadera S, Mansouri A, Connolly MB, Major P, MaT, Devinsky O, Weiner HL, Gonzalez-Martinez JA, Bingaman WE, Najm I, Gupta A, Ragheb J, Bhatia S, Steinbok P, Witiw CD, Widjaja E, Snead OC, Rutka JT. Resective Epilepsy Surgery for Tuberous Sclerosis in Children: Determining Predictors of Seizure Outcomes in a Multicenter Retrospective Cohort Study. *Neurosurgery.* ;77(4):517-24; discussion 524, 2015.

Widjaja E, Zamyadi M, Raybaud C, Snead OC, Doesburg SM, Smith ML. Disrupted Global and Regional Structural Networks and Subnetworks in Children with Localization-Related Epilepsy. *AJNR Am J Neuroradiol.*; 36(7):1362-8, 2015.

Sun HS

Wang H, Quirion R, Little PJ, Cheng Y, Feng ZP, **Sun HS**, Xu J, Zheng W. Forkhead box O transcription factors as possible mediators in the development of major depression. *Neuropharmacology.*; 99:527-37, 2015.

Chen WL, Barszczyk A, Turlova E, Deurloo M, Liu B, Yang BB, Rutka JT, Feng ZP, **Sun HS**. Inhibition of TRPM7 by carvacrol suppresses glioblastoma cell proliferation, migration and invasion. *Oncotarget.*; 6(18):16321-40, 2015.

Chen WL, Turlova E, Sun CL, Kim JS, Huang S, Zhong X, Guan YY, Wang GL, Rutka JT, Feng ZP, **Sun HS**. Xyloketal B suppresses glioblastoma cell proliferation and migration in vitro through inhibiting TRPM7-regulated PI3K/Akt and MEK/ERK signaling pathways. *Mar Drugs.*; 13(4):2505-25, 2015.

Zhao LY, Li J, Yuan F, Li M, Zhang Q, Huang YY, Pang JY, Zhang B, Sun FY, **Sun HS**, Li Q, Cao L, Xie Y, Lin YC, Liu J, Tan HM, Wang GL. Xyloketal B attenuates atherosclerotic plaque formation and endothelial dysfunction in apolipoprotein e deficient mice. *Mar Drugs.*; 13(4):2306-26, 2015.

Bin NR, Jung CH, Kim B, Chandrasegram P, Turlova E, Zhu D, Gaisano HY, **Sun HS**, Sugita S. Chaperoning of closed syntaxin-3 through Lys46 and Glu59 in domain 1 of Munc18 proteins is indispensable for mast cell exocytosis. *J Cell Sci.*; 128(10):1946-60, 2015.

Chen W, Xu B, Xiao A, Liu L, Fang X, Liu R, Turlova E, Barszczyk A, Zhong X, Sun CL, Britto LR, Feng ZP, **Sun HS**. TRPM7 inhibitor carvacrol protects brain from neonatal hypoxic-ischemic injury. *Mol Brain.*; 8:11. doi: 10.1186/s13041-015-0102-5. PubMed PMID: 25761704; PubMed Central PMCID: PMC4337201.

Sun HS, Xu B, Chen W, Xiao A, Turlova E, Alibraham A, Barszczyk A, Bae CY, Quan Y, Liu B, Pei L, Sun CL, Deurloo M, Feng ZP. Neuronal K(ATP) channels mediate hypoxic preconditioning and reduce subsequent neonatal hypoxic-ischemic brain injury. *Exp Neurol.*; 263:161-71, 2015.

Barszczyk A, **Sun HS**, Quan Y, Zheng W, Charlton MP, Feng ZP. Differential roles of the mevalonate pathway in the development and survival of mouse Purkinje cells in culture. *Mol Neurobiol.*; 51(3):1116-29, 2015.

Xiao AJ, Chen WL, Xu BF, Liu R, Turlova E, Barszczyk A, Sun CLF, Liu L, Deurloo M, Wang GL, Feng ZP, **Sun HS** (SA). Novel Marine Compound Xyloketal B Reduces Neonatal Hypoxic-Ischemic Brain Injury. *Marine Drugs.*; 13: 29-47, 2015.

Swardfager W

Marzolini S, **Swardfager W**, Alter DA, Oh PI, Tan Y, Goodman JM. Quality of life and psychosocial measures influenced by exercise modality in patients with coronary artery disease. *Eur J Phys Rehabil Med.*; 51(3):291-9, 2015.

Swardfager W, Herrmann N, Mazereeuw G, Lanctôt KL. Reply to: Serum zinc and the risk of depression in men: observations from a 20-year follow-up study. *Biol Psychiatry.*; 77(3):e13-4, 2015.

MacIntosh BJ, **Swardfager W**, Robertson AD, Tchistiakova E, Saleem M, Oh PI, Herrmann N, Stefanovic B, Lanctôt KL. Regional cerebral arterial transit time hemodynamics correlate with vascular risk factors and cognitive function in men with coronary artery disease. *AJNR Am J Neuroradiol.*; 36(2):295-301, 2015.

Santiago C, Herrmann N, **Swardfager W**, Saleem M, Oh PI, Black SE, Lanctôt KL. White Matter Microstructural Integrity Is Associated with Executive Function and Processing Speed in Older Adults with Coronary Artery Disease. *Am J Geriatr Psychiatry.*; 23(7):754-63, 2015.

Robertson AD, Crane DE, Rajab AS, **Swardfager W**, Marzolini S, Shirzadi Z, Middleton LE, MacIntosh BJ. Exercise intensity modulates the change in cerebral blood flow following aerobic exercise in chronic stroke. *Exp Brain Res.*; 233(8):2467-75, 2015.

Swardfager W, Yang P, Herrmann N, Lanctôt KL, Shah BR, Kiss A, Oh PI. Depressive symptoms predict non-completion of a structured exercise intervention for people with Type 2 diabetes. *Diabet Med.*; 33(4):529-36, 2015.

Saleem M, Herrmann N, **Swardfager W**, Eisen R, Lanctôt KL. Inflammatory Markers in Mild Cognitive Impairment: A Meta-Analysis. *J Alzheimers Dis.*;47(3):669-79, 2015.

Tong Y

Zhang Q, Fan L, Hou F, Dong A, Wang YX, and **Tong Y**: New insights into the RNA binding and E3 ubiquitin ligase activities of Roquins. *Scientific Reports.*; 5:15660, 2015.

Tyndale RF

Webb A, Papp AC, Curtis A, Newman LC, Pietrzak M, Seweryn M, Handelman SK, Rempala GA, Wang D, Graziosa E, **Tyndale RF**, Lerman C, Kelsoe JR, Mash DC, Sadee W. RNA sequencing of transcriptomes in human brain regions: protein-coding and non-coding RNAs, isoforms and alleles. *BMC Genomics.*; 16:990, 2015.

Loukola A, Buchwald J, Gupta R, Palviainen T, Hällfors J, Tikkanen E, Korhonen T, Ollikainen M, Sarin AP, Ripatti S, Lehtimäki T, Raitakari O, Salomaa V, Rose RJ, **Tyndale RF**, Kaprio J.

A Genome-Wide Association Study of a Biomarker of Nicotine Metabolism. *PLoS Genet.*; 11(9):e1005498, 2015.

Alsharari SD, King JR, Nordman JC, Muldoon PP, Jackson A, Zhu AZ, **Tyndale RF**, Kabbani N, Damaj MI. Effects of Menthol on Nicotine Pharmacokinetic, Pharmacology and Dependence in Mice. *PLoS One.*; 10(9):e0137070, 2015.

Dubroff JG, Doot RK, Falcone M, Schnoll RA, Ray R, **Tyndale RF**, Brody AL, Hou C, Schmitz A, Lerman C. Decreased Nicotinic Receptor Availability in Smokers with Slow Rates of Nicotine Metabolism. *J Nucl Med.*; 56(11):1724-9, 2015.

Kaufmann A, Hitsman B, Goelz PM, Veluz-Wilkins A, Blazekovic S, Powers L, Leone FT, Gariti P, **Tyndale RF**, Schnoll RA. Rate of nicotine metabolism and smoking cessation outcomes in a community-based sample of treatment-seeking smokers. *Addict Behav.*; 51:93-9, 2015.

Bergen AW, Michel M, Nishita D, Krasnow R, Javitz HS, Conneely KN, Lessov-Schlaggar CN, Hops H, Zhu AZ, Baurley JW, McClure JB, Hall SM, Baker TB, Conti DV, Benowitz NL, Lerman C, **Tyndale RF**, Swan GE; Transdisciplinary Research in Cancer of the Lung Research Team.. Drug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism, Prospective Abstinence, and Cigarette Consumption. *PLoS One.*; 10(7):e0126113, 2015.

Boileau I, **Tyndale RF**, Williams B, Mansouri E, Westwood DJ, Le Foll B, Rusjan PM, Mizrahi R, De Luca V, Zhou Q, Wilson AA, Houle S, Kish SJ, Tong J. The fatty acid amide hydrolase C385A variant affects brain binding of the positron emission tomography tracer [11C]CURB. *J Cereb Blood Flow Metab.*; 35(8):1237-40, 2015.

Tanner JA, Novalen M, Jatlow P, Huestis MA, Murphy SE, Kaprio J, Kankaanpää A, Galanti L, Stefan C, George TP, Benowitz NL, Lerman C, **Tyndale RF**. Nicotine metabolite ratio (3-hydroxycotinine/cotinine) in plasma and urine by different analytical methods and laboratories: implications for clinical implementation. *Cancer Epidemiol Biomarkers Prev*; 24(8):1239-46, 2015.

Tyndale RF, Zhu AZ, George TP, Cinciripini P, Hawk LW Jr, Schnoll RA, Swan GE, Benowitz NL, Heitjan DF, Lerman C; PGRN-PNAT Research Group.. Lack of Associations of CHRNA5-

A3-B4 Genetic Variants with Smoking Cessation Treatment Outcomes in Caucasian Smokers despite Associations with Baseline Smoking. *PLoS One.*; 10(5):e0128109, 2015.

Foti RS, **Tyndale RF**, Garcia KL, Sweet DH, Nagar S, Sharan S, Rock DA. "Target-Site" Drug Metabolism and Transport. *Drug Metab Dispos.*; 43(8):1156-68, 2015.

Le Foll B, **Tyndale RF**. Cannabinoids: Friend or foe? *Clin Pharmacol Ther.*; 97(6):528-31, 2015.

Zhu AZ, Cox LS, Ahluwalia JS, Renner CC, Hatsukami DK, Benowitz NL, **Tyndale RF**. Genetic and phenotypic variation in UGT2B17, a testosterone-metabolizing enzyme, is associated with BMI in males. *Pharmacogenet Genomics.*; 25(5):263-9, 2015.

Hamilton DA, Mahoney MC, Novalen M, Chenoweth MJ, Heitjan DF, Lerman C, **Tyndale RF**, Hawk LW Jr. Test-Retest Reliability and Stability of the Nicotine Metabolite Ratio Among Treatment-Seeking Smokers. *Nicotine Tob Res.*; 17(12):1505-9, 2015.

Tanner JA, Chenoweth MJ, **Tyndale RF**. Pharmacogenetics of nicotine and associated smoking behaviors. *Curr Top Behav Neurosci.*; 23:37-86, 2015.

Garcia KL, Coen K, Miksys S, Lê AD, **Tyndale RF**. Effect of Brain CYP2B Inhibition on Brain Nicotine Levels and Nicotine Self-Administration. *Neuropsychopharmacology.*; 40(8):1910-8, 2015.

McMillan DM, **Tyndale RF**. Nicotine Increases Codeine Analgesia Through the Induction of Brain CYP2D and Central Activation of Codeine to Morphine. *Neuropsychopharmacology.*; 40(7):1804-12, 2015.

Lerman C, Schnoll RA, Hawk LW Jr, Cinciripini P, George TP, Wileyto EP, Swan GE, Benowitz NL, Heitjan DF, **Tyndale RF**; PGRN-PNAT Research Group.. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. *Lancet Respir Med.*; 3(2):131-8, 2015.

Bandiera FC, Ross KC, Taghavi S, Delucchi K, **Tyndale RF**, Benowitz NL. Nicotine Dependence, Nicotine Metabolism, and the Extent of Compensation in Response to Reduced Nicotine Content Cigarettes. *Nicotine Tob Res.*; 17(9):1167-72, 2015.

Wassenaar CA, Ye Y, Cai Q, Aldrich MC, Knight J, Spitz MR, Wu X, Blot WJ, **Tyndale RF**. CYP2A6 reduced activity gene variants confer reduction in lung cancer risk in African American smokers--findings from two independent populations. *Carcinogenesis.*; 36(1):99-103, 2015.

Wassenaar CA, Conti DV, Das S, Chen P, Cook EH, Ratain MJ, Benowitz NL, **Tyndale RF**. UGT1A and UGT2B genetic variation alters nicotine and nitrosamine glucuronidation in european and african american smokers. *Cancer Epidemiol Biomarkers Prev.*; 24(1):94-104, 2015.

O'Loughlin J, Dugas EN, Brunet J, DiFranza J, Engert JC, Gervais A, Gray-Donald K, Karp I, Low NC, Sabiston C, Sylvestre MP, **Tyndale RF**, Auger N, Auger N, Mathieu B, Tracie B, Chaiton M, Chenoweth MJ, Constantin E, Contreras G, Kakinami L, Labbe A, Maximova K, McMillan E, O'Loughlin EK, Pabayo R, Roy-Gagnon MH, Tremblay M, Wellman RJ, Hulst A, Paradis G. Cohort Profile: The Nicotine Dependence in Teens (NDIT) Study. *Int J Epidemiol.*; 44(5):1537-46, 2015.

Tyndale RF and Garcia KLP. CYP-mediated Drug Metabolism within the Brain: A Role in Central Nervous System Response, Global Science and Technology Forum, Pharmacology and Pharmaceutical Science. 2015 10.5176/2345-783X_PHARMA15.43#sthash.6jfoMTk0.dpuf. of amodiaquine-induced liver injury in rats and mice. *J. Immunotoxicol.* 13(5): 694-712, 2015.

Utrecht J

Mak A, **Utrecht J**. The combination of anti-CTLA-4 and PD1^{-/-} mice unmasks the potential of isoniazid and nevirapine to cause liver injury. *Chem Res Toxicol.* 28(12): 2287-2291, 2015.

Utrecht J, Kaplowitz N. Inhibition of immune tolerance unmasks drug-induced allergic hepatitis. *Hepatology.* 62(2): 346-348, 2015.

Mak A, **Utrecht J**. The role of CD8 T cells in amodiaquine-induced liver injury in PD1^{-/-} mice cotreated with anti-CTLA-4. *Chem Res Toxicol.* 28(8): 1567-1573, 2015.

Mak A, **Utrecht J**. Immunization with amodiaquine-modified hepatic proteins prevents amodiaquine-induced liver injury. *J Immunotoxicol.* 12(4): 361-367, 2015.

Johnston A, **Utrecht J**. Current understanding of the mechanisms of idiosyncratic drug-induced-agranulocytosis. *Expert Opinion on Drug Metabolism & Toxicology.* 11(2):243-257, 2015.

Metushi IG, Hayes MA, **Utrecht J**. Treatment of PD-1^(-/-) mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients. *Hepatology.* 61(4):1332-1342, 2015.

Vedadi M

Sun Y, Bell JL, Carter D, Gherardi S, Poulos RC, Milazzo G, Wong JW, Al-Awar R, Tee AE, Liu PY, Liu B, Atmadibrata B, Wong M, Trahair T, Zhao Q, Shohet JM, Haupt Y, Schulte JH, Brown PJ, Arrowsmith CH, **Vedadi M**, MacKenzie KL, Hüttelmaier S, Perini G, Marshall GM, Braithwaite A, Liu T. WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma. *Cancer Res.*; 75(23):5143-54, 2015.

Zhu J, Sammons MA, Donahue G, Dou Z, **Vedadi M**, Getlik M, Barsyte-Lovejoy D, Al-awar R, Katona BW, Shilatifard A, Huang J, Hua X, Arrowsmith CH, Berger SL. Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. *Nature.*; 525(7568):206-11, 2015.

Curry E, Green I, Chapman-Rothe N, Shamsaei E, Kandil S, Cherblanc FL, Payne L, Bell E, Ganesh T, Srimongkolpithak N, Caron J, Li F, Uren AG, Snyder JP, **Vedadi M**, Fuchter MJ, Brown R. Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells. *Clin Epigenetics.* ; 7:84, 2015.

Grebien F, **Vedadi M**, Getlik M, Giambruno R, Grover A, Avellino R, Skucha A, Vittori S, Kuznetsova E, Smil D, Barsyte-Lovejoy D, Li F, Poda G, Schapira M, Wu H, Dong A, Senisterra G, Stukalov A, Huber KV, Schönegger A, Marcellus R, Bilban M, Bock C, Brown PJ, Zuber J, Bennett KL, Al-Awar R, Delwel R, Nerlov C, Arrowsmith CH, Superti-Furga G. Pharmacological targeting of the Wdr5-MLL interaction in C/EBP α N-terminal leukemia. *Nat Chem Biol.*; 11(8):571-8, 2015.

Sweis RF, Wang Z, Algire M, Arrowsmith CH, Brown PJ, Chiang GG, Guo J, Jakob CG, Kennedy S, Li F, Maag D, Shaw B, Soni NB, **Vedadi M**, Pappano WN. Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2. *ACS Med Chem Lett.*; 6(6):695-700, 2015.

Eram MS, Kuznetsova E, Li F, Lima-Fernandes E, Kennedy S, Chau I, Arrowsmith CH, Schapira M, **Vedadi M**. Kinetic characterization of human histone H3 lysine 36 methyltransferases, ASH1L and SETD2. *Biochim Biophys Acta.*; 1850(9):1842-8, 2015.

Smil D, Eram MS, Li F, Kennedy S, Szewczyk MM, Brown PJ, Barsyte-Lovejoy D, Arrowsmith CH, **Vedadi M**, Schapira M. Discovery of a Dual PRMT5-PRMT7 Inhibitor. *ACS Med Chem Lett.*; 6(4):408-12, 2015.

Nguyen H, Allali-Hassani A, Antonysamy S, Chang S, Chen LH, Curtis C, Emtage S, Fan L, Gheyi T, Li F, Liu S, Martin JR, Mendel D, Olsen JB, Pelletier L, Shatseva T, Wu S, Zhang FF, Arrowsmith CH, Brown PJ, Campbell RM, Garcia BA, Barsyte-Lovejoy D, Mader M, **Vedadi M**. LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2. *J Biol Chem.*; 290(22):13641-53, 2015.

Kaniskan HÜ, Szewczyk MM, Yu Z, Eram MS, Yang X, Schmidt K, Luo X, Dai M, He F, Zang I, Lin Y, Kennedy S, Li F, Dobrovetsky E, Dong A, Smil D, Min SJ, Landon M, Lin-Jones J, Huang XP, Roth BL, Schapira M, Atadja P, Barsyte-Lovejoy D, Arrowsmith CH, Brown PJ, Zhao K, Jin J, **Vedadi M**. A potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3). *Angew Chem Int Ed Engl.*; 54(17):5166-70, 2015.

Xu B, On DM, Ma A, Parton T, Konze KD, Pattenden SG, Allison DF, Cai L, Rockowitz S, Liu S, Liu Y, Li F, **Vedadi M**, Frye SV, Garcia BA, Zheng D, Jin J, Wang GG. Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. *Blood.*; 125(2):346-57, 2015.

Verma S

Connelly KA, Yan AT, Leiter LA, Bhatt DL, **Verma S**. Cardiovascular Implications of Hypoglycemia in Diabetes Mellitus. *Circulation.*; 132(24):2345-50, 2015.

Yau JW, Teoh H, **Verma S**. Endothelial cell control of thrombosis. *BMC Cardiovasc Disord.*; 15:130, 2015.

Verma S, Goodman SG, Mehta SR, Latter DA, Ruel M, Gupta M, Yanagawa B, Al-Omran M, Gupta N, Teoh H, Friedrich JO. Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials. *BMC Surg.*; 15:112, 2015.

Yanagawa B, Ruel M, Bonneau C, Lee MM, Chung J, Al Shouli S, Fagan A, Al Khalifa A, White CW, Yamashita MH, Currie ME, Teoh H, Mewhort HE, **Verma S**. Dual antiplatelet therapy use by Canadian cardiac surgeons. *J Thorac Cardiovasc Surg.*; 150(6):1548-54.e3, 2015.

Verma S, Eikelboom JW, Nidorf SM, Al-Omran M, Gupta N, Teoh H, Friedrich JO. Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials. *BMC Cardiovasc Disord.*; 15:96, 2015.

Nidorf SM, **Verma S**. Is There a Role for Colchicine in Acute Coronary Syndromes? *J Am Heart Assoc.*; 4(8):e002372, 2015.

Mantella LE, Quan A, **Verma S**. Variability in vascular smooth muscle cell stretch-induced responses in 2D culture. *Vasc Cell.*; 7:7, 2015.

Guzzardi DG, Barker AJ, van Ooij P, Malaisrie SC, Puthumana JJ, Belke DD, Mewhort HE, Svystonyuk DA, Kang S, **Verma S**, Collins J, Carr J, Bonow RO, Markl M, Thomas JD, McCarthy PM, Fedak PW. Valve Aortopathy: Insights From Wall Shear Stress Mapping. *J Am Coll Cardiol.*; 66(8):892-900, 2015. -Related Her

Zhu YM, Anderson TJ, Sikdar K, Fung M, McQueen MJ, Lonn EM, **Verma S**. Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention. *Arterioscler Thromb Vasc Biol.*; 35(10):2254-9, 2015.

Peterson MD, Mazine A, El Hamamsy I, Manlhiot C, Ouzounian M, MacArthur RG, Wood JR, Bozinovski J, Apoo J, Moon MC, Boodhwani M, Hassan A, **Verma S**, Dagenais F, Chu MW; Canadian Thoracic Aortic Collaborative Investigators. Knowledge, attitudes, and practice preferences of Canadian cardiac surgeons toward the management of acute type A aortic dissection. *J Thorac Cardiovasc Surg.*; 150(4):824-31.e1-5, 2015.

Law TK, Yan AT, Gupta A, Kajil M, Tsigoulis M, Singh N, **Verma S**, Gupta M. Primary Prevention of Cardiovascular Disease: Global Cardiovascular Risk Assessment and Management in Clinical Practice. *Eur Heart J - Quality of Care and Clinical Outcomes.*; 1(1):31-36, 2015.

Shavadia J, Norris CM, Graham MM, **Verma S**, Ali I, Baine KR. Symptomatic graft failure and impact on clinical outcome after coronary artery bypass grafting surgery: Results from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease registry. *Am Heart J.*; 169(6):833-40, 2015.

Hussain MA, **Verma S**, Gupta N, Al-Omran M. Carotid Artery Revascularization: What's the Best Strategy? *Circulation.*; 131(25):2226-31, 2015.

Ramadan A, Wheatcroft MD, Quan A, Singh KK, Lovren F, Dhingra N, Teoh H, Al-Omran M, Leong-Poi H, **Verma S**. Effects of long-term chloroquine administration on the natural history of aortic aneurysms in mice. *Can J Physiol Pharmacol.*; 93(8):641-8, 2015.

Fitchett DH, Hegele RA, **Verma S**. Cardiology patient page. Statin intolerance. *Circulation.*; 131(13):e389-91, 2015.

Lovren F, Teoh H, **Verma S**. Obesity and atherosclerosis: mechanistic insights. *Can J Cardiol.*; 31(2):177-83, 2015.

Nussenzweig SC, **Verma S**, Finkel T. The role of autophagy in vascular biology. *Circ Res.*; 116(3):480-8, 2015.

Chen YA, Deva D, Kirpalani A, Prabhudesai V, Marcuzzi DW, Graham JJ, **Verma S**, Jimenez-Juan L, Yan AT. Multimodality imaging for resuscitated sudden cardiac death. *J Cardiovasc Med (Hagerstown).*; 16 Suppl 1:S1-3, 2015.

Singh KK, Lovren F, Pan Y, Quan A, Ramadan A, Matkar PN, Ehsan M, Sandhu P, Mantella LE, Gupta N, Teoh H, Parotto M, Tabuchi A, Kuebler WM, Al-Omran M, Finkel T, **Verma S**. The essential autophagy gene ATG7 modulates organ fibrosis via regulation of endothelial-to-mesenchymal transition. *J Biol Chem.*; 290(5):2547-59, 2015.

Wallace JL

Blackler RW, De Palma G, Manko A, Da Silva GJ, Flannigan KL, Bercik P, Surette MG, Buret AG, **Wallace JL**. Deciphering the pathogenesis of NSAID-enteropathy using proton pump inhibitors and a hydrogen sulfide-releasing NSAID. *Am J Physiol* 308: G994-1003, 2015.

Magierowski M, Jasnos K, Drozdowicz D, Strzalka M, Ptak-Belowska A, Kwiecien S, **Wallace JL**, Brzozowski T. Endogenous prostaglandins and afferent sensory nerves in gastroprotective effect of hydrogen sulfide against stress-induced gastric lesions. *PLoS One* 10: e0118972, 2015.

Motta JP, Flannigan KL, Agbor TA, Beatty JK, Blackler RW, Workentine ML, Da Silva GJ, Wang R, Buret AG, **Wallace JL**. Hydrogen sulfide protects from colitis and restores intestinal microbiota biofilm and mucus production. *Inflammatory Bowel Diseases* 21: 1006-1017, 2015.

Flannigan KL, Agbor TA, Motta J-P, Ferraz JGP, Wang R, Buret AG, **Wallace JL**. Pro-resolution effects of hydrogen sulfide during colitis are mediated through hypoxia-inducible factor-1 α . *FASEB J* 29: 1591-1602, 2015.

Wallace JL, Blackler RW, Chan MV, da Silva GJ, Elsheikh W, Flannigan KL, Gamaniek I, Manko A, Wang L, Motta JP, Buret AG. Anti-inflammatory and cytoprotective actions of hydrogen sulphide: translation to therapeutics. *Antiox Redox Signal* 22: 398-410, 2015.

Blackler RW, Motta JP, Manko A, Workentine M, Surette MG, **Wallace JL**. Hydrogen sulfide protects against NSAID-enteropathy through modulation of bile and the microbiota. *Br J Pharmacol* 172: 992-1004, 2015.

Wallace JL, Wang R. Hydrogen sulfide-based therapeutics: exploiting a unique but ubiquitous gasotransmitter. *Nature Rev Drug Discovery* 14: 329-345, 2015.

Zayachkivska O, Havryluk O, Hrycevyh N, Bula N, Grushka O, **Wallace JL**. Cytoprotective effects of hydrogen sulfide in novel rat models of non-erosive esophagitis. *PLoS One* 9: e110688.

Elsheikh W, Blackler RW, Flannigan KL, **Wallace JL**. Enhanced chemopreventative effects of a hydrogen sulfide-releasing NSAID (ATB-346) in experimental colorectal cancer. *Nitric Oxide* 41: 131-137.

Warsh JJ

Zack M, Boileau I, Payer D, Chugani B, Lobo DS, Houle S, Wilson AA, **Warsh JJ**, Kish SJ. Differential cardiovascular and hypothalamic pituitary response to amphetamine in male pathological gamblers versus healthy controls. *J Psychopharmacol.*; 29(9):971-82, 2015.

Wells JW

Patowary S, Pisterzi LF, Biener G, Holz JD, Oliver JA, **Wells JW**, Raicu V. Experimental verification of the kinetic theory of FRET using optical microspectroscopy and obligate oligomers. *Biophys J.*; 108(7):1613-22, 2015.

Wells PG

Ramkissoon A, **Wells PG**. Methamphetamine oxidative stress, neurotoxicity, and functional deficits are modulated by nuclear factor-E2-related factor 2. *Free Radic Biol Med.*; 89:358-68, 2015.

Sweeting JN, **Wells PG**. New Zealand white rabbit progeny exposed in utero to methanol are resistant to skeletal anomalies reported for rodents, but exhibit a novel vertebral defect. *Reprod Toxicol.*; 58:104-10, 2015.

Miller-Pinsler L, **Wells PG**. Embryonic catalase protects against ethanol embryopathies in acatalasemic mice and transgenic human catalase-expressing mice in embryo culture. *Toxicol Appl Pharmacol.*; 287(3):232-9, 2015.

Miller-Pinsler L, Pinto DJ, **Wells PG**. Oxidative DNA damage in the in utero initiation of postnatal neurodevelopmental deficits by normal fetal and ethanol-enhanced oxidative stress in oxoguanine glycosylase 1 knockout mice. *Free Radic Biol Med.*; 78:23-9, 2015.

Wong AH

Ng E, Varaschin RK, Su P, Browne CJ, Hermainski J, Le Foll B, Pongs O, Liu F, Trudeau LE, Roder JC, **Wong AH**. Neuronal calcium sensor-1 deletion in the mouse decreases motivation and dopamine release in the nucleus accumbens. *Behav Brain Res.*; 301:213-25, 2015.

Shams TA, Foussias G, Zawadzki JA, Marshe VS, Siddiqui I, Müller DJ, **Wong AH**. The Effects of Video Games on Cognition and Brain Structure: Potential Implications for Neuropsychiatric Disorders. *Curr Psychiatry Rep.*; 17(9):71, 2015.

Wong AH, Josselyn SA. Caution When Diagnosing Your Mouse With Schizophrenia: The Use and Misuse of Model Animals for Understanding Psychiatric Disorders. *Biol Psychiatry.*; 79(1):32-8, 2015.

Zhai D, Lee FH, D'Souza C, Su P, Zhang S, Jia Z, Zhang L, **Wong AH**, Liu F. Blocking GluR2-GAPDH ameliorates experimental autoimmune encephalomyelitis. *Ann Clin Transl Neurol.*; 2(4):388-400, 2015.

Samsom JN, **Wong AH**. Schizophrenia and Depression Co-Morbidity: What We have Learned from Animal Models. *Front Psychiatry.*; 6:13, 2015.

Borlido C, Remington G, Graff-Guerrero A, Arenovich T, Hazra M, **Wong A**, Daskalakis ZJ, Mamo DC. Switching from 2 antipsychotics to 1 antipsychotic in schizophrenia: a randomized double-blind, placebo-controlled study. *J Clin Psychiatry.*; 77(1):e14-20, 2015.

Young LT

Bond DJ, Andreatza AC, Hughes J, Dhanoa T, Torres IJ, Kozicky JM, **Young LT**, Lam RW, Yatham LN. Association of peripheral inflammation with body mass index and depressive relapse in bipolar disorder. *Psychoneuroendocrinology.*; 65:76-83, 2015.

Kim HK, Andreazza AC, Elmi N, Chen W, **Young LT**. Nod-like receptor pyrin containing 3 (NLRP3) in the post-mortem frontal cortex from patients with bipolar disorder: A potential mediator between mitochondria and immune-activation. *J Psychiatr Res.*; 72:43-50, 2015.

Nierenberg AA, Hearing CM, Sande Mathias I, **Young LT**, Sylvia LG. Getting to wellness: The potential of the athletic model of marginal gains for the treatment of bipolar disorder. *Aust N Z J Psychiatry.*; 49(12):1207-14, 2015.

Yatham LN, Beaulieu S, Schaffer A, Kauer-Sant'Anna M, Kapczinski F, Lafer B, Sharma V, Parikh SV, Daigneault A, Qian H, Bond DJ, Silverstone PH, Walji N, Milev R, Baruch P, da Cunha A, Quevedo J, Dias R, Kunz M, **Young LT**, Lam RW, Wong H. Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial. *Mol Psychiatry.*; 21(8):1050-6, 2015.

Ou X, Crane DE, MacIntosh BJ, **Young LT**, Arnold P, Ameis S, Goldstein BI. CACNA1C rs1006737 genotype and bipolar disorder: Focus on intermediate phenotypes and cardiovascular comorbidity. *Neurosci Biobehav Rev.*; 55:198-210, 2015.

Nascimento C, Kim HK, **Young LT**, Mendonça KM, Grinberg LT, Lafer B, Andreazza AC. Glutathione-mediated effects of lithium in decreasing protein oxidation induced by mitochondrial complex I dysfunction. *J Neural Transm (Vienna).*; 122(6):741-6, 2015.

Parikh SV, Hawke LD, Velyvis V, Zaretsky A, Beaulieu S, Patelis-Siotis I, MacQueen G, **Young LT**, Yatham LN, Cervantes P. Combined treatment: impact of optimal psychotherapy and medication in bipolar disorder. *Bipolar Disord.*; 17(1):86-96, 2015.

Andreazza AC, **Young LT**. *Acta Psychiatr Scand.*; 131(5):397-8, 2015. Select item 25684243

Andreazza AC, Gildengers A, Rajji TK, Zuzarte PM, Mulsant BH, **Young LT**. Oxidative stress in older patients with bipolar disorder. *Am J Geriatr Psychiatry.*; 23(3):314-9, 2015.

Zack M

Payer DE, Guttman M, Kish SJ, Tong J, Strafella A, **Zack M**, Adams JR, Rusjan P, Houle S, Furukawa Y, Wilson AA, Boileau I. [¹¹C]-(+)-PHNO PET imaging of dopamine D(2/3) receptors in Parkinson's disease with impulse control disorders. *Mov Disord.*; 30(2):160-6, 2015.

Pushparaj A, Kim AS, Musiol M, Zangen A, Daskalakis ZJ, **Zack M**, Winstanley CA, Le Foll B. Differential Involvement of the Agranular vs Granular Insular Cortex in the Acquisition and Performance of Choice Behavior in a Rodent Gambling Task. *Neuropsychopharmacology.*; 40(12):2832-42, 2015.

Zack M, Boileau I, Payer D, Chugani B, Lobo DS, Houle S, Wilson AA, Warsh JJ, Kish SJ. Differential cardiovascular and hypothalamic pituitary response to amphetamine in male pathological gamblers versus healthy controls. *J Psychopharmacol.*; 29(9):971-82, 2015.

Biback C, **Zack M**. The Relationship between Stress and Motivation in Pathological Gambling: A Focused Review and Analysis. *Current Addiction Reports (Invited Article)*, 2, 230-239, 2015,

Zawertailo LA

Cunningham JA, Kushnir V, Selby P, Tyndale RF, Zawertailo L, Leatherdale ST. Effect of Mailing Nicotine Patches on Tobacco Cessation Among Adult Smokers: A Randomized Clinical Trial. *JAMA Intern Med.*; 176(2):184-90, 2015.

Selby P, Hussain S, Voci S, Zawertailo L. Empowering smokers with a web-assisted tobacco intervention to use prescription smoking cessation medications: a feasibility trial. *Implement Sci.*; 10:139, 2015.

Zawertailo LA, Baliunas D, Ivanova A, Selby PL. Individualized Treatment for Tobacco Dependence in Addictions Treatment Settings: The Role of Current Depressive Symptoms on Outcomes at 3 and 6 Months. *Nicotine Tob Res.*; 17(8):937-45, 2015.

Kaduri P, Voci S, Zawertailo L, Chaiton M, McKenzie K, Selby P. Real-world effectiveness of varenicline versus nicotine replacement therapy in patients with and without psychiatric disorders. *J Addict Med.*; 9(3):169-76, 2015.

Zawertailo L, Voci S, Selby P. Depression status as a predictor of quit success in a real-world effectiveness study of nicotine replacement therapy. *Psychiatry Res.*; 226(1):120-7, 2015.

Zelner I

Zelner I, Matlow J, Hutson JR, Wax P, Koren G, Brent J, Finkelstein Y; Toxicology Investigators Consortium (ToxIC).. Acute Poisoning During Pregnancy: Observations from the Toxicology Investigators Consortium. *J Med Toxicol.*; 11(3):301-8, 2015.

Ph.D. Theses – Pharmacology Dept. University of Toronto (2015).

Chenoweth, Meghan (2015). Sources of Variation in Nicotine Metabolism and Associations with Smoking Abstinence in Adolescents and Adults.

Chiuccariello, Lina (2015). The Role of Dopamine in Cue-induced Craving (2015). A [11C]-(+)-PHNO PET Study in Tobacco-dependent Smokers.

Delano, Kaitlyn (2015). Utilizing Biomarkers to Assess Prevalence and Trends of Substance Use during Pregnancy in Canada.

Garcia, Kristine (2015). The Effects of Altering Brain CYP2B Activity on Nicotine Self-administration Behaviour and Nicotine Levels in the Brain.

Hatch, Jessica (2015). Biological and Clinical Correlates of Vascular Risk in Adolescent Bipolar Disorder.

Kim, Helena (2015). The Downstream Targets of Complex I Dysfunction in Bipolar Disorder.

Mazereeuw, Graham (2015). Omega-3 Fatty Acids and Depressive Symptoms in Coronary Artery Disease.

Pal, Mrinal (2015). The HLA Complex Group 9 Gene Modification Study in Major Psychosis.

Poon, Shirley (2015). Hair as A Matrix for Assessing Polybrominated Diphenyl Ether (PBDE) Exposure in Animals and Humans.

Shen, Yen Fu (2015). The Role of the Dopamine D1-D2 Receptor Heteromer in Brain Reward Function (2015). Relevance to Drug Addiction and Depression.

M.Sc. Theses – Pharmacology Dept., University of Toronto (2015).

Burston, Jillian (2015). Acute Effects of Cannabis on Young Drivers' Performance of Driving Related Skills.

Biback, Candice (2015). Empathy and the Subjective-behavioural Effects of D1 and D2 Receptor Blockade in Pathological Gamblers.

Cho, Tiffany (2015). 3-Methylcholanthrene Induces Chylous Ascites and Lethality in Tiparp Knockout Mice.

Chow, Cheuk Kiu (2015). The Safety of Diclectin® in Breastfeeding.

Jiang, David Lai (2015). Deficiency of Myelin Proteins during Brain Development in Fragile X Mice.

Kwan, Andrew (2015). Epigenetic Study of Plasma Circulating DNA in Prostate Cancer.

Mansoursadeghi-Gilan, Tara (2015). Real-world Effectiveness of Bupropion versus Varenicline for Smoking Cessation (2015). Exploring the Role of Metabolic and Personality Variables.